

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM644733

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
KALA PHARMACEUTICALS, INC.		05/04/2021	Corporation:
RECEIVING PARTY DATA			
Name:	OXFORD FINANCE LLC		
Street Address:	115 SOUTH UNION STREET, SUITE 300		
City:	ALEXANDRIA		
State/Country:	VIRGINIA		
Postal Code:	22314		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 24			
Property Type	Number	Word Mark	
Registration Number:	4585580	KALA	
Registration Number:	5401810	KALA	
Registration Number:	5722929	INVELTYS	
Serial Number:	87492692	VYSTALI	
Serial Number:	87492700	LORPREXIO	
Serial Number:	87492704	SUVEOUS	
Serial Number:	87492707	VISOOVA	
Registration Number:	6301667	EYSUVIS	
Serial Number:	87694665	ZUDREYA	
Serial Number:	87694667	SOODRYA	
Registration Number:	5968321	INVELTYS	
Registration Number:	5968322	INVELTYS	
Registration Number:	5968323	V	
Registration Number:	5968324	V	
Serial Number:	88062537	ALMIENCE	
Serial Number:	88062546	LUXTREON	
Serial Number:	88062540	REYALBIS	
Registration Number:	5951075	AMPPLIFY	
Registration Number:	6310078	EYSUVIS	
TRADEMARK			

CH \$615.00 4585580

Property Type	Number	Word Mark
Registration Number:	6310079	EYSUVIS
Serial Number:	88797027	RELFAYRA
Serial Number:	88797025	SPEDLYF
Serial Number:	90126591	EYSUVIS
Serial Number:	90126587	EYSUVIS

CORRESPONDENCE DATA

Fax Number: 6173106001
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Phone: 6173105234
Email: prezase@gtlaw.com
Correspondent Name: Eugenia A. Prezas
Address Line 1: Greenberg Traurig, LLP
Address Line 2: One International Place, Suite 2000
Address Line 4: Boston, MASSACHUSETTS 02110

NAME OF SUBMITTER:	Eugenia A. Prezas
SIGNATURE:	/Eugenia A. Prezas/
DATE SIGNED:	05/06/2021

Total Attachments: 76
source=IPSecurityAgreementMay2021#page1.tif
source=IPSecurityAgreementMay2021#page2.tif
source=IPSecurityAgreementMay2021#page3.tif
source=IPSecurityAgreementMay2021#page4.tif
source=IPSecurityAgreementMay2021#page5.tif
source=IPSecurityAgreementMay2021#page6.tif
source=IPSecurityAgreementMay2021#page7.tif
source=IPSecurityAgreementMay2021#page8.tif
source=IPSecurityAgreementMay2021#page9.tif
source=IPSecurityAgreementMay2021#page10.tif
source=IPSecurityAgreementMay2021#page11.tif
source=IPSecurityAgreementMay2021#page12.tif
source=IPSecurityAgreementMay2021#page13.tif
source=IPSecurityAgreementMay2021#page14.tif
source=IPSecurityAgreementMay2021#page15.tif
source=IPSecurityAgreementMay2021#page16.tif
source=IPSecurityAgreementMay2021#page17.tif
source=IPSecurityAgreementMay2021#page18.tif
source=IPSecurityAgreementMay2021#page19.tif
source=IPSecurityAgreementMay2021#page20.tif
source=IPSecurityAgreementMay2021#page21.tif
source=IPSecurityAgreementMay2021#page22.tif
source=IPSecurityAgreementMay2021#page23.tif

source=IPSecurityAgreementMay2021#page24.tif
source=IPSecurityAgreementMay2021#page25.tif
source=IPSecurityAgreementMay2021#page26.tif
source=IPSecurityAgreementMay2021#page27.tif
source=IPSecurityAgreementMay2021#page28.tif
source=IPSecurityAgreementMay2021#page29.tif
source=IPSecurityAgreementMay2021#page30.tif
source=IPSecurityAgreementMay2021#page31.tif
source=IPSecurityAgreementMay2021#page32.tif
source=IPSecurityAgreementMay2021#page33.tif
source=IPSecurityAgreementMay2021#page34.tif
source=IPSecurityAgreementMay2021#page35.tif
source=IPSecurityAgreementMay2021#page36.tif
source=IPSecurityAgreementMay2021#page37.tif
source=IPSecurityAgreementMay2021#page38.tif
source=IPSecurityAgreementMay2021#page39.tif
source=IPSecurityAgreementMay2021#page40.tif
source=IPSecurityAgreementMay2021#page41.tif
source=IPSecurityAgreementMay2021#page42.tif
source=IPSecurityAgreementMay2021#page43.tif
source=IPSecurityAgreementMay2021#page44.tif
source=IPSecurityAgreementMay2021#page45.tif
source=IPSecurityAgreementMay2021#page46.tif
source=IPSecurityAgreementMay2021#page47.tif
source=IPSecurityAgreementMay2021#page48.tif
source=IPSecurityAgreementMay2021#page49.tif
source=IPSecurityAgreementMay2021#page50.tif
source=IPSecurityAgreementMay2021#page51.tif
source=IPSecurityAgreementMay2021#page52.tif
source=IPSecurityAgreementMay2021#page53.tif
source=IPSecurityAgreementMay2021#page54.tif
source=IPSecurityAgreementMay2021#page55.tif
source=IPSecurityAgreementMay2021#page56.tif
source=IPSecurityAgreementMay2021#page57.tif
source=IPSecurityAgreementMay2021#page58.tif
source=IPSecurityAgreementMay2021#page59.tif
source=IPSecurityAgreementMay2021#page60.tif
source=IPSecurityAgreementMay2021#page61.tif
source=IPSecurityAgreementMay2021#page62.tif
source=IPSecurityAgreementMay2021#page63.tif
source=IPSecurityAgreementMay2021#page64.tif
source=IPSecurityAgreementMay2021#page65.tif
source=IPSecurityAgreementMay2021#page66.tif
source=IPSecurityAgreementMay2021#page67.tif
source=IPSecurityAgreementMay2021#page68.tif
source=IPSecurityAgreementMay2021#page69.tif
source=IPSecurityAgreementMay2021#page70.tif
source=IPSecurityAgreementMay2021#page71.tif

source=IPSecurityAgreementMay2021#page72.tif
source=IPSecurityAgreementMay2021#page73.tif
source=IPSecurityAgreementMay2021#page74.tif
source=IPSecurityAgreementMay2021#page75.tif
source=IPSecurityAgreementMay2021#page76.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of May 4, 2021 by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “**Lender**” and collectively, the “**Lenders**”), and KALA PHARMACEUTICALS, INC., a Delaware corporation with an address at 490 Arsenal Way, Suite 120, Watertown, MA 02472 (“**Grantor**”).

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Borrower (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the “**Loan Agreement**,” capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Borrower, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement and other Loan Documents (as defined in the Loan Agreement), Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or

hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

KALA PHARMACEUTICALS, INC.

490 Arsenal Way
Suite 120
Watertown, MA 02472
Attn: Mary Reumuth, Chief Financial
Officer

By: 
Name: Mary Reumuth
Title: Chief Financial Officer

COLLATERAL AGENT:

Address of Lender:

OXFORD FINANCE LLC

115 South Union Street
Suite 300
Alexandria, VA 22314

By: _____
Name: _____
Title: _____

{Signature Page to IP Security Agreement}

TRADEMARK
REEL: 007282 FRAME: 0804

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

KALA PHARMACEUTICALS, INC.

490 Arsenal Way
Suite 120
Watertown, MA 02472
Attn: Mary Reumuth, Chief Financial
Officer


By: _____
Name: _____
Title: _____

COLLATERAL AGENT:

Address of Lender:

OXFORD FINANCE LLC

115 South Union Street
Suite 300
Alexandria, VA 22314

By:  _____
Name: Colette H. Featherly
Title: Senior Vice President

[Signature Page to IP Security Agreement]

TRADEMARK
REEL: 007282 FRAME: 0805

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

(See attached.)

PATENT FAMILY: JIL001

TITLE(S): JIL001.A SPEC. = SURFACE MODIFICATION OF PARTICLES
JIL001.B SPEC. = DRUGS AND GENE CARRIER PARTICLES THAT RAPIDLY MOVE THROUGH MUCCOUS BARRIERS
JIL001.C SPEC. = DRUGS AND GENE CARRIER PARTICLES THAT RAPIDLY MOVE THROUGH MUCCOUS BARRIERS

Assignee: John's Hopkins University (JHU)
In-licensed from JHU

OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
JIL001.AUSPR	60/539,773 (United States)	28-Jan-2004	Provisional 1		EXPIRED
JIL001.BUSPR	60/579,533 (United States)	14-Jun-2004	Provisional 2		EXPIRED
JIL001.CWO	PCT/US2005/002556 (PCT Int'l) [Pub'd as WO 2005/072710 on 11-Aug-2005]	28-Jan-2005	PCT of Provisionals JIL002.A & JIL002.B		EXPIRED/IN NATIONAL STAGE
JIL001.CIEP	05722577.3 (European Patent Office) [Pub'd as EP1713514 on 25- Oct-2006]	28-Jan-2005	Nat'l Stage of JIL001.CWO		PENDING (Allowed)
JIL001.CIUS	10/587,512 (United States) [Pub'd as US 2008/0166414 on 10-Jul-2008]	8-Nov-2007 (371 Date)	Nat'l Stage of JIL001.CWO	US 8,957,034 on 17 Feb-2015	ISSUED
JIL001.CIUS2	14/620,333 (United States) [Pub'd as US 2016/0256404 on 8-Sep-2016]	12-Feb-2015	DIV of JIL001.CIUS		ABANDONED

JIL001.C/US3	15/988,615 (United States) [Pub'd as US 2018/0344656 on -Dec2018	24-May-2018	CON of JIL001.C/US2		Abandoned
JIL001.C/US4	17/012,976 (United States)	04-Sep-2020	DIV of JIL001.C/US3		PENDING

PATENT FAMILY: JIL002

TITLE(S): COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUS

Assignee: John's Hopkins University (JHU)

In-licensed from JHU

GER REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
JIL002.A/USPR	60/843,282 (United States)	8-Sep-2006	Provisional		EXPIRED
JIL002.B/WO	PCT/US2007/019522 (PCT Intl) [Pub'd as WO2008/030557 on 13-Mar-2008]	7-Sep-2007	PCT of JIL002.A/USPR		EXPIRED/IN NATIONAL STAGE
JIL002.B/AU	2007/292902 (Australia) [Pub'd as AU2007292902 on 13-Mar-2008]	7-Sep-2007	Nat'l Stage of JIL002.B/WO	AU 2007292902 on 05-Dec- 2013	GRANTED
JIL002.B/AU2	2013/257518 (Australia)	7-Sep-2007	DIV of JIL002.B/AU		ABANDONED
JIL002.B/CA	2,663,003 (Canada) [Pub'd as CA2663003 on 13- Mar-2008]	7-Sep-2007	Nat'l Stage of JIL002.B/WO	CA2663003 on 13-Feb-2018	GRANTED
JIL002.B/EP	07837876.7 (European Patent Office)	7-Sep-2007	Nat'l Stage of JIL002.B/WO	EP2061433 B1 on 02/16/2011	REVOKED on Appeal of Opposition by Vectura Ltd.

	[Pub'd as EP2061433 on 27-May-2009]				
JIL002.B/HK-EP	09110690.3 (Hong Kong)	7-Sep-2007	HK Registration of JIL002.B/EP		Registered EP - Revoked with JIL002.B/EP
JIL002.B/JP	2009-527,422 (Japan) [Pub'd as JP2010502713 on 28-Jan-2010]	7-Sep-2007	Nat'l Stage of JIL002.B/WO		ABANDONED
JIL002.B/JP2	2013-110,583 (Japan) [Pub'd as JP2013163697 on 22-Aug-2013]	7-Sep-2007	DIV of JIL002.B/JP		ABANDONED
JIL002.B/JP3	2014-256,264 (Japan) [Pub'd as JP201557438 on 26-Mar-2015]	7-Sep-2007	DIV of JIL002.B/JP2	JP6297481 on 02-Mar-2018	GRANTED
JIL002.B/US	12/310,751 (United States) [Pub'd as US 2010/0215580 on 26-Aug-2010]	22-Jan-2010 (371 Date)	Nat'l Stage of JIL002.B/WO		ABANDONED
JIL002.B/US2	13/692,442 (United States) [Pub'd as US 2013/0164343 on 27-Jun-2013]	3-Dec-2012	CON of JIL002.B/US		ABANDONED
JIL002.B/US3	15/196,178 (United States) [Pub'd as 2017/0095566 on 06-Apr-2017]	29-Jun-2016	CON of JIL002.B/US2		ABANDONED
JIL002.B/US4	15/982,447 (United States) [Pub'd as US2018/0264135 on 20-Sep-2018]	17-May-2018	CON of JIL002.B/US3		ABANDONED
JIL002.B/US5	16/936,220 (United States)	22-Jul-2020	DIV of JIL002.B/US4		PENDING

PATENT FAMILY: JIL003

TITLE(S) COMPOSITIONS AND METHODS RELATING TO REDUCED MUCCADHESION

Assignee: John's Hopkins University (JHU)
In-licensed from JHU

OUR REF. NO	APPLN NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
JIL003.AUSPR	61/410,539 (United States)	11/5/2010	Provisional		EXPIRED
JIL003.B/US	13/289,196 (United States) [Pub'd as US2012/0121718 on 17-May-2012]	4-Nov-2011	US ORD of JIL003.AUSPR		ABANDONED
JIL003.B/US2	13/853,406 (United States) [Pub'd as US2013/0236556 on 12-Sep-2013]	29-Mar-2013	CON of JIL003.B/US		ABANDONED
JIL003.B/US3	15/065,017 (United States) [Pub'd as US 2017/0007542 on 12-Jan-2017]	9-Mar-2016	CON of JIL003.B/US2		ABANDONED
JIL003.B/US4	16/510,355 (United States)		CON of JIL003.B/US3		PENDING
JIL003.B/WO	PCT/US2011/059321 (PCT Int'l) [Pub'd as WO2012/061703 on 10-May-2012]	4-Nov-2011	PCT of JIL003.AUSPR		EXPIRED/IN NATIONAL STAGE
JIL003.B/AU	2011/323250 (Australia) [Pub'd as AU2011323250 on 02-May-2013]	4-Nov-2011	Nat'l Stage of JIL003.B/WO	AU2011323250 on 03-Mar-2016	GRANTED
JIL003.B/CA	2,816,977 (Canada) [Pub'd as CA2816977 on 12- May-2012]	4-Nov-2011	Nat'l Stage of JIL003.B/WO	CA2816977 on 29-Oct-2019	GRANTED

JIL003.B/CA2	3,054,532 (Canada)	4-Nov-2011	DIV of JIL003.B/CA		PENDING
JIL003.B/EP	11838873.5 (European Patent Office) [Pub'd as EP2635254 on 11-Sep-2013]	4-Nov-2011	Nat'l Stage of JIL003.B/WO	EP2635254 on 15-May-2019	GRANTED
JIL003.B/EP-DE	(Germany)	4-Nov-2011	Validation of JIL003.B/EP		
JIL003.B/EP-FR	(France)	4-Nov-2011	Validation of JIL003.B/EP		
JIL003.B/EP-UK	(Great Britain)	4-Nov-2011	Validation of JIL003.B/EP		
JIL003.B/HK-EP	13110775.5 (Hong Kong) [Pub'd as HK1183433 on 27-Dec-2013]	4-Nov-2011	HK Registration of JIL003.B/EP		ABANDONED

PATENT FAMILY: JIL004

TITLE(S): RAPID DIFFUSION OF LARGE POLYMERIC NANOPARTICLES IN THE MAMMALIAN BRAIN

Assignee: John's Hopkins University (JHU)
In-licensed from JHU

GER REF. NO.	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P.	PATENT NO. & ISSUE DATE	STATUS
JIL004.A/USPR	61/381,754 (United States)	10-Sep-2010	Provisional 1		EXPIRED
JIL004.B/WO	PCT/US2011/051195 (PCT Intl) [Pub'd as WO2012/039979 on 29-Mar-2012]	12-Sep-2011	PCT of JIL004.A/USPR		EXPIRED/IN NATIONAL STAGE

JIL004.B/US	13/821,320 (United States) [Pubd as US2013/0183244 on 18-Jul-2013]	7-Mar-2013 (371 Date)	Natl Stage of JIL004.B/WO	US 10,307,372 on 04-Jun-2019	ISSUED
-------------	---	--------------------------	---------------------------	------------------------------	--------

PATENT FAMILY: JIL005

TITLE(S): JIL005.A SPEC: NANOPARTICLES WITH ENHANCED MUCOSAL PENETRATION OR DECREASED INFLAMMATION
 JIL005.B SPEC: MUCUS PENETRATING GENE CARRIERS
 JIL005.F SPEC: NANOPARTICLES WITH ENHANCED MUCOSAL PENETRATION OR DECREASED INFLAMMATION
 JIL005.G SPEC: NANOPARTICLE FORMULATIONS WITH ENHANCED MUCOSAL PENETRATION

Assignee: John's Hopkins University (JHU)
 In-licensed from JHU

GER REF. NO	APPLN NO & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO & ISSUE DATE	STATUS
JIL005.A/USPR	61/431,521 (United States)	11-Jan-2011	Provisional 1		EXPIRED
JIL005.B/USPR	61/440,647 (United States)	8-Feb-2011	Provisional 2		EXPIRED
JIL005.B/WO	PCT/US2012/024344 (PCT Int'l) [Pubd as WO2012/109363 on 16-Aug-2012]	8-Feb-2012	PCT of JIL005.B/USPR		EXPIRED/IN NATIONAL STAGE
JIL005.B/US	13/984,386 (United States) [Pubd as US2013/0323313 on 05-Dec-2013]	8-Aug-2013 (371 Date)	Natl Stage of JIL005.B/WO	US 9,327,037 on 03-May-2016	ISSUED
JIL005.B/US2	15/144,077 (United States) [Pubd as US2016/0243257 on 25-Aug-2016]	2-May-2016	CON of JIL005.B/US	US 9,675,711 on 13-Jun-2017	ISSUED
JIL005.B/US3	15/592,383 (United States) [Pubd as US2017/0246320 on 31-Aug-2017]	11-May-2017	CON of JIL005.B/US2	US 10,729,786 on 04-Aug-2020	ISSUED

JIL005.C/USPR	61/570,405 (United States)	14-Dec-2011	Provisional 3		EXPIRED
JIL005.D/USPR	61/570,413 (United States)	14-Dec-2011	Provisional 4		EXPIRED
JIL005.E/USPR	61/588,350 (United States)	19-Jan-2012	Provisional 5		EXPIRED
JIL005.F/WO	PCT/US2012/069882 (PCT Intl) [Pub'd as WO2013/090804 on 20-Jun-2013]	14-Dec-2012	PCT of JIL005.C/USPR, JIL005.D/USPR, & JIL005.B/WO		EXPIRED/IN NATIONAL STAGE
JIL005.F/AU	2012/351994 (Australia) [Pub'd as AU2012351994 on 24-Jul-2014]	14-Dec-2012	Nat'l Stage of JIL005.F/WO	AU2012351994 on 18-Feb-2016	GRANTED
JIL005.F/AU2	2016/200683 (Australia) [Pub'd as AU2016200683 on 18-Feb-2016]	14-Dec-2012	DIV of JIL005.F/AU	AU2016200683 on 23-Nov- 2017	GRANTED
JIL005.F/CA	2,859,046 (Canada) [Pub'd as CA2859046 on 20- Jun-2013]	14-Dec-2012	Nat'l Stage of JIL005.F/WO	CA2859046 on 22-Oct-2019	GRANTED
JIL005.F/CN	201280069271.1 (China) [Pub'd as CN104105507 on 15-Oct-2015]	14-Dec-2012	Nat'l Stage of JIL005.F/WO	CN104105507 on 2-Mar-2020	GRANTED
JIL005.F/EP	12820997.0 (European Patent Office) [Pub'd as EP2790733 on 22- Oct-2014]	14-Dec-2012	Nat'l Stage of JIL005.F/WO	EP2790733 on 30-Oct-2019	GRANTED
JIL005.F/EP-DE	(Germany)		Validation of JIL005.F/EP		
JIL005.F/EP-FR	(France)		Validation of JIL005.F/EP		

JIL005.F/EP-GB	(Great Britain)			Validation of JIL005.F/EP		
JIL005.F/HK-CN	15103577.8 (Hong Kong) [Pub'd as HK1203052 on 16-Oct-2015]	14-Jan-1900		HK Registration of JIL005.F/CN		REGISTERED
JIL005.F/JP	2014-547513 (Japan) [Pub'd as JP2015505855 on 26-Feb-2015]	14-Dec-2012		Nat'l Stage of JIL005.F/MO	JP6308679 on 23-Mar-2018	GRANTED
JIL005.F/JP2	2016-78766 (Japan) [Pub'd as JP2016128522 on 14-Jul-2016]	14-Dec-2012		DIV of JIL005.F/JP	JP6590750 on 27-Sep-2019	GRANTED
JIL005.F/JP3	2018-17235 (Japan) [Pub'd as JP2018065862 on 26-Apr-2018]	12-Dec-2012		DIV of JIL005.F/JP		PENDING (Published)
JIL005.F/KR	10-2014-7019535 (South Korea)	14-Dec-2012		Nat'l Stage of JIL005.F/MO		ABANDONED
JIL005.F/RU	2014128578 (Russian Federation) [Pub'd as RU2014128578 on 10-Feb-2016]	14-Dec-2012		Nat'l Stage of JIL005.F/MO	RU2631599 on 25-Sep-2017	GRANTED
JIL005.F/US	14365,963 (United States) [Pub'd as US2014/0329913 on 06-Nov-2014]	16-Jun-2014 (371 Date)		Nat'l Stage of JIL005.F/MO		ABANDONED
JIL005.F/US2	17/184,087 (United States)	24-Feb-2021		CON of JIL005.F/US		PENDING
JIL005.G/MO	PCT/US2013/022387 (PCT Int'l) [Pub'd as WO2013/110028 on 25-Jul-2013]	21-Jan-2013		PCT of JIL005.E/USPR & JIL005.B/MO & JIL005.F/MO		EXPIRED/IN NATIONAL STAGE
JIL005.G/AU	2013/209452 (Australia) [Pub'd as AU2013209452 on 28-Aug-2014]	21-Jan-2013		Nat'l Stage of JIL005.G/MO	AU2013209452 on 18-Feb-2016	GRANTED

JIL005.G/AU2	2016/200707 (Australia) [Pub'd as AU2016200707 on 05-Nov-2015]	21-Jan-2013	DIV of JIL005.G/AU	AU2016200707 on 03-Aug-2017	GRANTED
JIL005.G/CA	2,863,632 (Canada) [Pub'd as CA 2863632 on 25- Jul-2013]	21-Jan-2013	Nat'l Stage of JIL005.G/WO	CA2,863,632 on 11-Jul-2017	GRANTED
JIL005.G/CN2	201380015484.0 (China) [Pub'd as CN104936620 on 23-Sep-2015]	21-Jan-2013	DIV of JIL005.G/CN	CN104936620 on 09-Aug-2019	GRANTED
JIL005.G/EP	13702703.3 (European Patent Office) [Pub'd as EP2804632 on 26- Nov-2014]	21-Jan-2013	Nat'l Stage of JIL005.G/WO	EP2804632 on 18-Sep-2019	GRANTED
JIL005.G/EP-DE	(Germany)		Validation of JIL005.G/EP		
JIL005.G/EP-FR	(France)		Validation of JIL005.G/EP		
JIL005.G/EP-GB	(Great Britain)		Validation of JIL005.G/EP		
JIL005.G/HK-CN	16103338.7 (Hong Kong) [Pub'd as HK1215380 on 26- Aug-2016]	21-Jan-2013	HK Registration of JIL005.G/CN2	HK1215380 on 08-May-2020	GRANTED
JIL005.G/KR	10-2014-7023088 (South Korea (Rep. of Korea)) [Pub'd as KR20140138639 on 04-Dec-2014]	21-Jan-2013	Nat'l Stage of JIL005.G/WO	KR 10-11811917(B1) on 22- Dec-2017	GRANTED
JIL005.G/RU	2014133858 (Russian Federation) [Pub'd as RU2014133858 on 30-Mar-2016]	21-Jan-2013	Nat'l Stage of JIL005.G/WO	RU2598627 on 27-Sep-2016	GRANTED
JIL005.G/US	14/373,324 (United States) [Pub'd as US2015/0297531 on 22-Oct-2015]	18-July-2014 (371 Date)	Nat'l Stage of JIL005.G/WO	US 9,415,020 on 16-Aug-2016	ISSUED

JIL005.G/US2	15/207,803 (United States) [Pub'd as US2016/0317459 on 03-Nov-2016]	12-Jul-2016	CON of JIL005.G/US	US 9,629,813 on 25-Apr-2017	ISSUED
---------------------	--	-------------	--------------------	-----------------------------	--------

PATENT FAMILY: JIL005

TITLE(S): LIPID-BASED DRUG CARRIERS FOR RAPID PENETRATION THROUGH MUCUS LININGS

Assignee: John's Hopkins University (JHU)

In-licensed from JHU

OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
JIL006.A/USPR	61/642,776 (United States)	4-May-2013	Provisional 1		EXPIRED
JIL006.B/WO	PCT/US2013/039731 (PCT Int'l) [Pub'd as WO2013/166498 on 07-Nov-2013]	6-May-2013	PCT of JIL006.A/USPR		EXPIRED/IN NATIONAL STAGE
JIL006.B/AU	2013/256008 (Australia) [Pub'd as AU2013256008 on 20-Nov-2014]	6-May-2013	Nat'l Stage of JIL006.B/WO	AU2013256008 on 9-Jun-2016	GRANTED
JIL006.B/CA	2,872,519 (Canada) [Pub'd as CA2872519 on 07- Nov-2013]	6-May-2013	Nat'l Stage of JIL006.B/WO	CA2872519 on 5-Sep-2017	GRANTED
JIL006.B/EP	13722265.9 (European Patent Office) [Pub'd as EP2849728 on 25- Mar-2015]	6-May-2013	Nat'l Stage of JIL006.B/WO		PENDING (Published)
JIL006.B/HK-EP	15109178.8 (Hong Kong) [Pub'd as HK1208377 on 04- Mar-2016]	6-May-2013	HK Registration of JIL006.B/EP		PENDING (Published)

JIL006 B/JP	2015-5-10507 (Japan) [Pub'd as JP201515992 on 04-Jun-2015]	6-May-2013	Nat'l Stage of JIL006 B/WO	JP6392209 on 31-Aug-2018	GRANTED
JIL006 B/JP2	2017-220782 (Japan) [Pub'd as JP201839836 on 15-Mar-2018]	6-May-2013	DIV of JIL006 B/JP		ABANDONED
JIL006 B/US	14/397,828 (United States) [Pub'd as US2015/0086484 on 26-Mar-2015]	29-Oct-2014 (371 date)	Nat'l Stage of JIL006 B/WO	US 9,889,208 on 13-Feb-2018	ISSUED
JIL006 B/US2	15/890,156 (United States) [Pub'd as US2018/0169263 on 21-Jun-2018]	6-Feb-2018	CON of JIL006 B/US	US 10,556,017 on 11-Feb-2020	ISSUED

PATENT FAMILY: JIL003

TITLE(S): MUCOUS PENETRATING PARTICLES WITH HIGH MOLECULAR WEIGHT AND DENSE COATINGS

Assignee: John's Hopkins University (JHU)
In-licensed from JHU

OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
JIL008 A/USPR	62/248,432 (United States)	30-Oct-2015	Provisional 1		EXPIRED
JIL008 B/WO	PCT/US2016/059661 (PCT Intl) [Pub'd as WO2017/075565 on 04-May-2017]	31-Oct-2016	PCT of JIL008 A/USPR		EXPIRED/IN NATIONAL STAGE
JIL008 B/US	15/771,961 (United States) [Pub'd as US2018/221293 on 09-Aug-2018]	31-Oct-2016	Nat'l Stage of JIL008 B/WO	US10,668,025 on 02-Jun-2020	ISSUED

PATENT FAMILY: JIL009

TITLES) MUCUS-PENETRATING BUDESONIDE NANOSUSPENSION ENEMA FOR LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE

Assignee: John's Hopkins University (JHU)

In-licensed from JHU

GRN REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
JIL009 A/PROV	62/532,883 (United States)	14-Jul-2017			EXPIRED
JIL009 B/US	16/036,819 (United States) [Pub'd as US2019/0015349 on 17-Jan-2019]	16-Jul-2018	Non-provisional of JIL009 A/PROV		ABANDONED
JIL009 B/US2	16/828,222 (United States) [Pub'd as US2020/0306202 on 01-Oct-2020]	24-Mar-2020	CON of JIL009 B/US		PENDING

TRADEMARK**REEL: 007282 FRAME: 0819**

PATENT FAMILY: GBS01
TITLE(S): SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT

Assignee: John's Hopkins University (JHU)
 Sublicensed from GrayBug LLC (now Graybug Vision, Inc.)

GBR REF. NO	APPLN NO & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO & ISSUE DATE	STATUS
GBS01.A/USPR	61/308,035 (United States)	25-Feb-2010	Provisional 1		EXPIRED
GBS01.B/USPR	61/308,402 (United States)	25-Feb-2010	Provisional 2		EXPIRED
GBS01.C/USPR	61/308,053 (United States)	25-Feb-2010	Provisional 3		EXPIRED
GBS01.D/MWO	PCT/US2011/026321 (PCT Int'l) [Pub'd as WO2011/106702 on 01-Sep-2011]	25-Feb-2011	PCT of GBS01.A, B, & .C/USPR		EXPIRED/IN NATIONAL STAGE
GBS01.D/ICA	2,791,278 (Canada) [Pub'd as CA2791278 on 01- Sep-2011]	25-Feb-2011	Nat'l Stage of GBS01.D/MWO	CA2791278 on 24-Nov-2015	GRANTED
GBS01.D/IEP	11748181.2 (European Patent Office) [EP2538929A2 on 02-Jan-2013]	25-Feb-2011	Nat'l Stage of GBS01.D/MWO		PENDING (Published)
GBS01.D/US	13/581,454 (United States) [Pub'd as US2012/0321719 on 20-Dec-2012]	8/27/2012 (371 Date)	Nat'l Stage of GBS01.D/MWO	US 8,889,193 on 18-Nov-2014	ISSUED

GBS01.D/US2	14/521,904 (United States) [Pub'd as US2015/0044270 on 15-Feb-2015]	23-Oct-2014	CON of GBS01.D/US	US 9,566,242 on 14-Feb-2017	ISSUED
GBS01.D/US3	15/138,132 (United States) [Pub'd as US 2016/0235674 on 18-Aug-2016]	25-Apr-2016	CON of GBS01.D/US2	US 9,937,130 on 10-Apr-2018	ISSUED
GBS01.D/US4	15/884,158 (United States) [Pub'd as US 2018/0161277 on 14-Jun-2018]	30-Jan-2018	CON of GBS01.D/US3	US 10,369,107 on 18-Aug-2019	ISSUED
GBS01.D/US5	16/502,359 (United States) [Pub'd as US2019/0321297 on 24-Oct-2019]	03-Jul-2019	CON of GBS01.D/US4		PENDING (Published)

PATENT FAMILY: GBS02

TITLE(S) GBS02.C SPEC. CONTROLLED RELEASE FORMULATIONS FOR THE DELIVERY OF HIF-1 INHIBITORS
GBS02.D SPEC. NONLINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS

Assignee: John's Hopkins University (JHU)

Sublicensed from GrayBug LLC (now Graybug Vision, Inc.)

OUR REF. NO	APPLN NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
GBS02.A/USPR	61/611,931 (United States)	16-Mar-2012	Provisional 1		EXPIRED
GBS02.B/USPR	61/611,975 (United States)	16-Mar-2012	Provisional 2		EXPIRED
GBS02.C/US	13/797,506 (United States) [Pub'd as US2013/0274217 on 17-Oct-2013]	12-Mar-2013	US ORD Filing of GBS02.A/USPR	US 8,962,577 on 24-Feb-2015	ISSUED

GBS02.C/US2	14/599,853 (United States) [Pub'd as US2015/0141359 on 21-May-2015]	19-Jan-2015	CON of GBS02.C/US	US 9,950,072 on 24-Apr-2018	ISSUED
GBS02.C/MO	PCT/US2013/030533 (PCT Int'l) [Pub'd as WO2013/136343 on 19-Sep-2013]	12-Mar-2013	PCT of GBS02.A/USPR		EXPIRED/IN NATIONAL STAGE
GBS02.C/AU	2013/232297 (Australia) [Pub'd as AU2013232297 on 23-Oct-2014]	12-Mar-2013	Nat'l Stage of GBS02.C/MO	AU2013232297 on 28-Apr-2016	GRANTED
GBS02.C/CA	2,867,381 (Canada) [Pub'd as CA 2867381 on 19- Sep-2013]	12-Mar-2013	Nat'l Stage of GBS02.C/MO	CA 2,867,381 on 20-Sep-2016	GRANTED
GBS02.C/CN	2013-80025514.6 (China) [Pub'd as CN104363924 on 18-Feb-2015]	12-Mar-2013	Nat'l Stage of GBS02.C/MO	CN104363924 on 17-Apr-2018	GRANTED
GBS02.C/EA	2014-91710 (Eurasian Patent Organization) [Pub'd as EA201491710 on 30-Apr-2015]	12-Mar-2013	Nat'l Stage of GBS02.C/MO	EA032552 on 28-Jun-2019	GRANTED
GBS02.C/EP	13711263.7 (European Patent Office) [Pub'd as EP2825206 on 21- Jan-2015]	12-Mar-2013	Nat'l Stage of GBS02.C/MO	EP2825207 on 19-Aug-2020	GRANTED
GBS02.C/EP-DE			Validation of GBS02.C/EP		
GBS02.C/EP-FR			Validation of GBS02.C/EP		
GBS02.C/EP-GB			Validation of GBS02.C/EP		
GBS02.C/HK-EP	15106964.2 (Hong Kong) [Pub'd as HK1206270 on 08- Jan-2016]	12-Mar-2013	HK Registration of GBS02.C/EP		PENDING (Published)

GBS02.C/JP	2015-500518 (Japan) [Pub'd as JP2015511987 on 23-Apr-2015]	12-Mar-2013	Natl Stage of GBS02.C/WO	JP5883539 on 15-Mar-2016	GRANTED
GBS02.C/JP2	2015-500519 (Japan) [Pub'd as JP2015509986 on 28-Feb-2017]	12-Mar-2013	DIV of GBS02.C/JP	JP6138904 on 12-May-2017	GRANTED
GBS02.C/JP3	2017-087537 (Japan) [Pub'd as JP2017125075 on 14-Jun-2018]	26-Apr-2017	DIV of GBS02.C/JP2	JP6371438 on 20-Jul-2018	GRANTED
GBS02.D/US	13/797,531 (United States) [Pub'd as US2013/0272994 on 17-Oct-2013]	12-Mar-2013	US ORD Filing of GBS02.B/USPR	US10,159,743 on 25-Dec-2018	ISSUED
GBS02.D/US2	16/182,261 (United States) [Pub'd as US2019/0070302 on 07-Mar-2019]	06-Nov-2018	CON of GBS02.D/US	US10,933,144 on 02-Mar-2021	ISSUED
GBS02.D/US3	17/184,152 (United States)	24-Feb-2021	CON of GBS02.D/US2		PENDING
GBS02.D/WO	PCT/US2013/030536 (PCT Int'l) [Pub'd as WO2013/138346 on 19-Sep-2013]	12-Mar-2013	PCT of GBS02.B/USPR		EXPIRED/IN NATIONAL STAGE
GBS02.D/AU	2013/232300 (Australia) [Pub'd as AU2013232300 on 02-Oct-2014]	12-Mar-2013	Natl Stage of GBS02.D/WO	AU2013232300 on 31-Mar-2016	GRANTED
GBS02.D/CA	2,867,203 (Canada) [Pub'd as CA2867203 on 19- Sep-2013]	12-Mar-2013	Natl Stage of GBS02.D/WO	CA 2,867,203 on 20-Sep-2016	GRANTED
GBS02.D/CN	201380025826.7 (China) [Pub'd as CN104394891 on 04-Mar-2015]	12-Mar-2013	Natl Stage of GBS02.D/WO	CN104394891 on 16-Apr-2019	GRANTED
GBS02.D/EA	2014-91711 (Eurasian Patent Organization [Pub'd as EA201491711 on 31-Mar-2015])	12-Mar-2013	Natl Stage of GBS02.D/WO	EA030318 on 31-Jul-2018	GRANTED

GBS02.D/EP	13712059.8 (European Patent Office) [Pub'd as EP2825207 on 21-Jan-2015]	12-Mar-2013	Natl Stage of GBS02.D/MWO		PENDING (Published)
GBS02.D/HK-EP	15106961.5 (Hong Kong) [Pub'd as HK1206268 on 08-Jan-2016]	12-Mar-2013	HK Registration of GBS02.D/EP		PENDING (Published)
GBS02.D/JP	2015-509986 (Japan)	12-Mar-2013	Natl Stage of GBS02.D/MWO	JP6138904 on 31-May-2017	GRANTED

PATENT FAMILY: GBS03

TITLES) GBS03.A SPEC. GLUCOCORTICOID-LOADED NANOPARTICLES FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTION
 GBS03.B SPEC. GLUCOCORTICOID-LOADED NANOPARTICLES FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTION AND NEOVASCULARIZATION
 GBS03.C SPEC. GLUCOCORTICOID-LOADED NANOPARTICLES FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTION AND NEOVASCULARIZATION
 Assignee: John's Hopkins University (JHU)
 In-licensed from JHU

GBR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
GBS03.A/USPR	62/037,000 (United States)	13-Aug-2014	Provisional 1		EXPIRED
GBS03.B/USPR	62/139,561 (United States)	27-Mar-2015	Provisional 2		EXPIRED
GBS03.C/MWO	PCT/US2015/043478 (PCT Int'l) [Pub'd as WO2016/025215 on 18-Feb-2016]	3-Aug-2015	PCT of GBS03.A/USPR & GBS03.B/USPR		EXPIRED/IN NATIONAL STAGE
GBS03.C/CA	2,957,764 (Canada) [Pub'd as CA2957764 on 13-Aug-2014]	3-Aug-2015	Natl Stage of GBS03.C/MWO	CA 2957764 on 2 Jul 2019	GRANTED

GBS03.C/US	15/502,732 (United States) [Pub'd as US2017/0157147 on 8-Jun-2017]	8-Feb-2017 (371 Date)	371 of GBS03.C/MO	US 10,195,212 on 05-Feb-2019	GRANTED
-------------------	---	--------------------------	-------------------	------------------------------	---------

PATENT FAMILY: GBS05

TITLE(S): GBS05.C SPEC. SUNTINIB FORMULATIONS AND METHODS FOR USE THEREOF IN THE TREATMENT OF GLAUCOMA
GBS05.D SPEC. SUNTINIB FORMULATIONS AND METHODS FOR USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS

Assignee: John's Hopkins University (JHU)
Sublicensed from Graybug LLC (now Graybug Vision, Inc.)

GBS REF. NO	APPLN. NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
GBS05.A/USPR	62/092,118 (United States)	15-Dec-2014	Provisional 1		EXPIRED
GBS05.B/USPR	62/139,306 (United States)	27-Mar-2015	Provisional 2		EXPIRED
GBS05.C/MO	PCT/US2015/065678 (PCT Int'l) [Pub'd as WO2016/100380 on 23-Jun-2016]	15-Dec-2015	PCT 1 of GBS05.A & B/USPR		EXPIRED/ NATIONAL STAGE
GBS05.C/US	15/536,272 (United States) [Pub'd as US2017/0360750 on 21-Dec-2017]	12-Dec-2015	Natl' Stage of GBS05.C/MO	US 10,525,034 on 07-Jan-2020	ISSUED
GBS05.C/US2	16/692,691 (United States)	22-Nov-2019	CON of GBS05.C/US		PENDING
GBS05.C/CN	201580074275.2 (China) [Pub'd as CN107278151 on 20-Oct-2017]	12-Dec-2015	Natl' Stage of GBS05.C/MO		PENDING (Published)

GBS05.C/EP	15831100.1 (Europe) [Pub'd as EP3233058 on 25-Oct-2017]	12-Dec-2015	Nat'l Stage of GBS05.C/WO		PENDING (Published)
GBS05.C/HK-EP	18103515.0 (Hong Kong) [Pub'd as HK1243942 on 27-Jul-2018]		HK Registration of GBS05.C/EP		PENDING (Published)
GBS05.C/JP	2017-550467 (Japan) [Pub'd as JP2018500394 on 11-Nov-2018]	12-Dec-2015	Nat'l Stage of GBS05.C/WO		PENDING (Published)
GBS05.D/WO	PCT/US2015/065894 (PCT Int'l) [Pub'd as WO2016/100392 on 23-Jun-2016]	15-Dec-2015	PCT2 of GBS05.A & B/USPR		EXPIRED/ IN NATIONAL STAGE
GBS05.D/US	15/032,986 (United States) [Pub'd as US2017/0273901 on 28-Sep-2017]	28-Apr-2016	US Nat'l of GBS05.D/WO		PENDING (Published)
GBS05.D/US2	16/357,195 (United States) [Pub'd as US2019/0275001 on 12-Sep2019]	18-Mar-2019	CON of GBS05.D/US		PENDING (Published)
GBS05.D/AE	P6000725/2017 (United Arab Emirates)	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING
GBS05.D/AU	2015362621 (Australia) [Pub'd as AU2015362621 on 13-Jul-2017]	15-Dec-2015	Nat'l Stage of GBS05.D/WO	2015362621 on 02-May-2019	GRANTED
GBS05.D/BR	BR1120170127067 (Brazil) [Pub'd as BR112017012706 on 13-Mar-2018]	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING (Published)
GBS05.D/CA	2,972,075 (Canada) [Pub'd as CA2972075 on 23-Jun-2016]	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING (Published)
GBS05.D/CN	201580074390.X (China) [Pub'd as CN107205940 on 26-Sep-2017]	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING (Published)

GBS05.D/EP	15820019.6 (European Patent Office) [Pub'd as EP3233056 on 25-Oct-2017]	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING (Published)
GBS05.D/HK-EP	18100757.3 (Hong Kong) [Pub'd as HK1241281 on 08-Jun-2018]		HK Registration of GBS05.D/EP	PENDING (Published)
GBS05.D/IL	252943 (Israel)	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING
GBS05.D/IN	201717024282 (India) [Pub'd as 41/2017 on 13-Oct-2017]	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING (Published)
GBS05.D/JP	2017-550467 (Japan) [Pub'd as JP2017537985 on 21-Dec-2017]	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING (Published)
GBS05.D/MX	MX/a/2017/007873 (Mexico) [Pub'd as MX2017007873 on 06-Nov-2017]	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING (Published)
GBS05.D/OM	OM/P/2017/00171 (Oman)	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING
GBS05.D/QA	QA/201706/00267 (Qatar)	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING
GBS05.D/RU	2017123358 (Russian Federation)	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING
GBS05.D/SA	517381718 (Saudi Arabia)	15-Dec-2015	Nat'l Stage of GBS05.D/WO	PENDING

PATENT FAMILY - KP001

TITLE(S) FUNCTIONALIZED POLY(ETHERANHYDRIDE) BLOCK COPOLYMERS

Assignee: Kala

OUR REF NO	APPL'N NO & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO & ISSUE DATE	STATUS
KP001.A/USPR	60/635,280 (United States)	10-Dec-2004	Provisional		EXPIRED
KP001.B/WO	PCT/US2005/044658 (PCT Int'l) [Pub'd as WO 2006/063249 on 15-Jun-2006]	9-Dec-2005	PCT of KP001.A/USPR		EXPIRED/ IN NATIONAL STAGE
KP001.B/CA	2,590,098 (Canada) [Pub'd as CA2590098 on 15- Jun-2006]	9-Dec-2005	Nat'l Stage	CA 2590098 on 31-Mar-2015	GRANTED
KP001.B/EP	05853543.6 (European Patent Office) [Pub'd as EP1856179 on 21- Nov-2017]	9-Dec-2005	Nat'l Stage	EP1856179 on 15-May-2013	GRANTED
KP001.B/DE	(Germany)		Validation of KP001.B/EP		GRANTED
KP001.B/ES	(Spain)		Validation of KP001.B/EP		GRANTED
KP001.B/FR	(France)		Validation of KP001.B/EP		GRANTED
KP001.B/GB	(Great Britain)		Validation of KP001.B/EP		GRANTED
KP001.B/US	11/721,123 (United States) [Pub'd as US 2010/0003337 on 07-Jan-2010]	9-Dec-2005(21-Sep-2009(371 Date))	Nat'l Stage of KP001.B/WO	US 8,354,476 on 15-Jan-2013	ISSUED

PATENT FAMILY: KP002

TITLE(S) COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS

Assignee: Kala

OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP002.AUSPR	61/642,261 (United States)	3-May-2012	Provisional		EXPIRED
KP002.B/US	13/886,514 (United States) [Pub'd as US 2013/0316009 on 28-Nov-2013]	3-May-2013	US ORD Filing of KP002.AUSPR	US10,668,041 on 23-Jun-2020	ISSUED
KP002.B/US2	16/883,778 (United States) [Pub'd as US2020/0289405 on 17-Sep-2020]	26-May-2020	DIV of KP002.B/US		PENDING
KP002.B/WO	PCT/US2013/039499 (PCT Int'l) [Pub'd as WO2013/166408 on 7-Nov-2013]	3-May-2013	PCT of KP002.AUSPR		EXPIRED/IN NATIONAL STAGE
KP002.B/AU	2013/256064 (Australia) [Pub'd as AU2013256064 on 04-Jan-2018]	3-May-2013	Nat'l Stage of KP002.B/WO	AU2013256064 on 19-Apr-2018	GRANTED
KP002.B/AU2	2018202074 (Australia)	3-May-2013	DIV on KP002.B/AU	AU2018202074 on 31-Mar-2020	GRANTED
KP002.B/AU3	2020201184 (Australia)	19-Feb-2020	DIV on KP002.B/AU2		PENDING
KP002.B/CA	2,871,745 (Canada) [Pub'd as CA2871745 on 07- Nov-2013]	3-May-2013	Nat'l Stage of KP002.B/WO		PENDING (Published)

KP002.B/EP	13723350.8 (European Patent Office) [Pub'd as EP2844227 on 11-Mar-2015]	3-May-2013	Nat'l Stage of KP002.B/WO	EP2844227 on 18-Nov-2020	GRANTED
KP002.B/DE	(Germany)		Validation of KP001.B/EP		GRANTED
KP002.B/GB	(Great Britain)		Validation of KP001.B/EP		GRANTED
KP002.B/FR	(France)		Validation of KP001.B/EP		GRANTED
KP002.B/EP2	20208225.1 (Europe) [Pub'd as EP3808339 on 21-Apr-2021]	3-May-2013	DIV of KP002.B/EP		PENDING
KP002.B/HK-EP	15108778.4 (Hong Kong) [Pub'd as HK1208160 on 26-Feb-2016]	3-May-2013	HK Registration of KP002.B/EP		PENDING (Published)
KP002.B/JP	2015-510486 (Japan) [Pub'd as JP2015-515990A1 on 4-Jun-2015]	3-May-2013	Nat'l Stage of KP002.B/WO	JP630040 on 29-Jun-2018	GRANTED
KP002.B/JP2	2018-117609 (Japan)	3-May-2013	DIV of KP002.B/JP	JP6816084 on 20-Jan-2021	GRANTED
KP002.B/JP3	2020-144057 (Japan)	08-Aug-2020	DIV of KP002.B/JP2		PENDING
KP002.B/KR	10-2014-7033575 (South Korea) [Pub'd as KR 10-2015-004909A on 13-Jan-2015]	3-May-2013	Nat'l Stage of KP002.B/WO	KR10-2154880 on 04-Sep-2020	GRANTED

PATENT FAMILY - KP003

TITLE(S) NANOCRYSTALS COMPOSITION AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS

US cases assigned to JHU w/ a license back to Kalta and ex-US cases co-owned by Kalta and JHU

OUR REF. NO.	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P.	PATENT NO. & ISSUE DATE	STATUS
KP003.A/USPR	61/642,227 (United States)	3-May-2012	Provisional 1		EXPIRED
KP003.B/US	13/886,493 (United States) [Pub'd as US2013/0323179 on 05-Dec-2013]	3-May-2013	US ORD Filing of KP003.A/USPR	US 9,056,057 on 16-Jun-2015	ISSUED
KP003.B/US2	14/731,972 (United States) [Pub'd as US2015/0265543 on 24-Sep-2015]	5-Jun-2016	CON of KP003.B/US	US 9,393,213 on 19-Jul-2016	ISSUED
KP003.B/US3	14/731,921 (United States) [Pub'd as US2015/0265542 on 24-Sep-2015]	5-Jun-2015	CON of KP003.B/US	US 9,393,212 on 19-Jul-2016	ISSUED
KP003.B/US4	15/187,552 (United States) [Pub'd as US 2016/0287526 on 6-Oct-2016]	20-Jun-2016	CON of KP003.B/US3	US 9,532,955 on 03-Jan-2017	ISSUED
KP003.B/US5	15/354,704 (United States) [Pub'd as US2017/0128378 on 11-May-2017]	17-Nov-2016	CON of KP003.B/US4	US 9,737,491 on 22-Aug-2017	ISSUED
KP003.B/US6	15/616,799 (United States) [Pub'd as US2017/0266120 on 21-Sep-2017]	7-Jun-2017	CON of KP003.B/US5	US 10,058,511 on 28-Aug-2018	ISSUED
KP003.B/US7	15/976,736 (United States) [Pub'd as US2018/0256508 on 13-Sep-2018]	10-May-2018	CON of KP003.B/US6	US 10,736,854 on 11-Aug-2020	ISSUED
KP003.B/US8	16/923,980 (United States)	08-Jul-2020	CON of KP003.B/US7		PENDING
KP003.B/WO	PCT/US2013/039467 (PCT)	3-May-2013	PCT of KP003.A/USPR		EXPIRED/ IN NATIONAL STAGE

	(Pub'd as WO2013/166385 on 07-Nov-2013)					
KP003.B/AU	2013/256130 (Australia) [Pub'd as AU2013256130 on 21-Dec-2017]	3-May-2013	Nat'l Stage of KP003.B/WO	AU2013256130 on 5-Apr-2018	GRANTED	
KP003.B/AU2	2018/201772 (Australia) [Pub'd as AU2018201772 on 05-Apr-2018]	13-Mar-2018	DIV of K003.B/AU	AU2018201772 on 04-Jun-2020	GRANTED	
KP003.B/AU3	2020/203213 (Australia)	18-Apr-2020	DIV of KP003.B/AU2		PENDING	
KP003.B/CA	2,871,778 (Canada) [Pub'd as CA2871778 on 07-Nov-2013]	3-May-2013	Nat'l Stage of KP003.B/WO		PENDING (Published)	
KP003.B/EP	13724670.8 (European Patent Office) [Pub'd as EP2844295 on 11-Mar-2015]	3-May-2013	Nat'l Stage of KP003.B/WO		PENDING (Published)	
KP003.B/HK-EP	15108780.0 (Hong Kong) [Pub'd as HK1208162 on 26-Feb-2016]	3-May-2013	HK Registration of KP003.B/EP		PENDING (Published)	
KP003.B/JP	2015-510480 (Japan) [Pub'd as JP2015519330 on 09-Jul-2015]	3-May-2013	Nat'l Stage of KP003.B/WO	JP6360039 on 29-Jun-2018	GRANTED	
KP003.B/JP2	2018-117644 (Japan)	3-May-2013	DIV of KP003.B/JP	JP6816065 on 20-Jan-2021	GRANTED	
KP003.B/JP3	2020-152328 (Japan)	20-Sep-2020	DIV of KP003.B/JP2		PENDING	
KP003.B/KR	10-2014-7033571 (South Korea) [Pub'd as KR2015-0006868(A) on 19-Jan-2015]	3-May-2013	Nat'l Stage of KP003.B/WO	KR-2140989 on 04-Aug-2020	GRANTED	

KP003 B/K/R2	10-2020-7022063 (South Korea)	3-May-2013	DIV of KP003 B/K/R	PENDING
--------------	----------------------------------	------------	--------------------	---------

PATENT FAMILY: KP004

TITLES) Prov 1= COMPOSITIONS AND METHODS UTILIZING POL (VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS
All Other PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS

US cases assigned to JHU w/ a license back to Kaiti and ex-US cases exclusively owned by Kaiti

OUR REF. NO	APPL'N NO & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO & ISSUE DATE	STATUS
KP002, A/USPR	61/642,261 (United States)	3-May-2012	Provisional 1		EXPIRED
KP004, A/USPR	61/642,313 (United States)	3-May-2012	Provisional 2		EXPIRED
KP004, B/USPR	61/738,949 (United States)	18-Dec-2012	Provisional 3		EXPIRED
KP004, C/USPR	61/784,701 (United States)	14-Mar-2013	Provisional 4		EXPIRED
KP004, D/US	13/886,602 (United States) [Pub'd as US2013/0316006 on 28-Nov-2013]	3-May-2013	US ORD of Provisionals 1-4		ABANDONED
KP004, D/US2	13/886,658 (United States) [Pub'd as US2013/0316001 on 28-Nov-2013]	3-May-2013	Non-Provisional of Prov. 1-4		ABANDONED
KP004, D/US3	15/992,494 (United States) [Pub'd as US2018/0271782 on 27-Sep-2018]	30-May-2018	CON of KP004, D/US		ABANDONED

KP004.D/US4	16/945,398 (United States)	31-Jul-2020	CON of KP004.D/US3		PENDING
KP004.D/WO	PCT/US2013/039540 (PCT Int'l) [Pub'd as WO2013/166436 on 7-Nov-2013]	3-May-2013	PCT of Provisionals 1-4		EXPIRED/ IN NATIONAL STAGE
KP004.D/AU	2013/256092 (Australia) [Pub'd as AU2013256092 on 30-Oct-2014]	3-May-2013	Natl' Stage of KP004.D/WO	AU2013256092 on 08-Mar-2018	GRANTED
KP004.D/AU2	2018-201215 (Australia)	20-Feb-2018	DIV of KP004.D/AU	AU2018201215 on 28-May- 2020	GRANTED
KP004.D/AU3	2020/023052 (Australia)	08-May-2020	DIV of KP004.D/AU2		PENDING
KP004.D/BR	BR112014027296 (Brazil) [Pub'd as BR112014027296 on 18-Jul-2017]	3-May-2013	Natl' Stage of KP004.D/WO		PENDING (Published)
KP004.D/CA	2,871,748 (Canada) [Pub'd as CA2871748 on 07- Nov-2013]	3-May-2013	Natl' Stage of KP004.D/WO		PENDING (Published)
KP004.D/CL	2014-2956 (Chile) [Pub'd as CL2014002956 on 02-Oct-2015]	3-May-2013	Natl' Stage of KP004.D/WO	CL59,839 on 11-Jun-2020	GRANTED
KP004.D/CL2	3433-2019 (Chile)	3-May-2013	DIV of KP004.D/CL		PENDING
KP004.D/CL3	3432-2019 (Chile)	3-May-2013	DIV of KP004.D/CL		PENDING
KP004.D/CN	201380035493.6 (China) [Pub'd as CN104661647 on 27- May-2015]	3-May-2013	Natl' Stage of KP004.D/WO		ABANDONED

KP004.D/CN2	202010551315 (China) [Pub'd as CN11714472 on 29-Sep-2020]	3-May-2013	DIV of KP004.D/CN		PENDING
KP004.D/CN3	202010551316 (China) [Pub'd as CN11700878 on 25-Sep-2020]	3-May-2013	DIV of KP004.D/CN		PENDING
KP004.D/CN4	202010551329 (China) [Pub'd as CN11700879 on 25-Sep-2020]	3-May-2013	DIV of KP004.D/CN		PENDING
KP004.D/CN5	202010551342 (China) [Pub'd as CN11700880 on 25-Sep-2020]	3-May-2013	DIV of KP004.D/CN		PENDING
KP004.D/EP	13723629.5 (European Patent Office) [Pub'd as EP2844223 on 11- Mar-2015]	3-May-2013	Natl Stage of KP004.D/WO		PENDING (Published)
KP004.D/EP2	(European Patent Office)		DIV of KP004.D/EP		In Progress
KP004.D/HK-CN	15109260.7 (Hong Kong) [Pub'd as HK120838 on 04- Mar-2016]	21-Sep-2015	HK Registration of KP004.D/CN		ABANDONED
KP004.D/HK-EP	15108779.3 (Hong Kong) [Pub'd as HK1208161 on 26- Feb-2016]	9-Sep-2015	HK Registration of KP004.D/EP		PENDING (Published)
KP004.D/HK-CN2	(Hong Kong) 42021028083.0 (Hong Kong)	26-Mar-2021	HK Registration of KP004.D/CN2		PENDING
KP004.D/HK-CN3	2021027919.6 (Hong Kong)	3/24/2021	HK Registration of KP004.D/CN3		PENDING
KP004.D/HK-CN4	42021027920.4 (Hong Kong)	3/24/2021	HK Registration of KP004.D/CN3		PENDING

KP004.D/HK-CNS	42021027921.2 (Hong Kong)	3/24/2021	HK Registration of KP004.D/CN3			PENDING
KP004.D/JP	2015-5-10490 (Japan) [Pub'd as JP2015519331 on 09-Jul-2015]	3-May-2013	Nat'l Stage of KP004.D/WO	JP6720443 on 22-Jun-2020		GRANTED
KP004.D/JP2	2019-182856 (Japan)	3-May-2013	DIV of KP004.D/JP			PENDING
KP004.D/JP3	2020-193338 (Japan)	3-May-2013	DIV of KP004.D/JP2			PENDING
KP004.D/KR	10-2014-7033577 (South Korea) [Pub'd as KR2015-0006869 on 19-Jan-2015]	3-May-2013	Nat'l Stage of KP004.D/WO			ABANDONED
KP004.D/KR2	10-2021-7002733 (South Korea)	3-May-2013	DIV of KP004.D/KR			PENDING
KP004.D/MX	MX/a/2014/013315 (Mexico) [Pub'd as MX2014013315 on 10-Sep-2015]	3-May-2013	Nat'l Stage of KP004.D/WO			PENDING (Allowed)
KP004.D/MX2	MX/a/2020/007227 (Mexico)	3-May-2013	DIV of KP004.D/MX			PENDING
KP004.D/NZ	700875 (New Zealand) [Pub'd as NZ700875 on 31- Mar-2017]	3-May-2013	Nat'l Stage of KP004.D/WO	NZ700875 on 07/04/2017		GRANTED
KP004.D/NZ2	728721 (New Zealand) [Pub'd as NZ728721 on 25- May-2018]	31-Jan-2017	DIV of KP004.D/NZ	NZ728721 on 08/28/2018		GRANTED
KP004.D/NZ3	733080 (New Zealand) [Pub'd as NZ733080 on 22- Dec-2017]	21-Jun-2017	DIV of KP004.D/NZ2	NZ733080 on 03/23/2018		GRANTED

KP004.D/NZ4	741873 (New Zealand)	23-Apr-2018	DIV of KP004.D/NZ2	NZ741873 on 30-Jul-2019	GRANTED
KP004.D/NZ5	742004 (New Zealand)	27-Apr-2018	DIV of KP004.D/NZ2	NZ742004 on 30-Jul-2019	GRANTED
KP004.D/NZ6	742005 (New Zealand)	27-Apr-2018	DIV of KP004.D/NZ2	NZ742005 on 30-Jul-2019	GRANTED
KP004.D/TH	1401006565 (Thailand) [Pub'd as TH167678 on 07-Sep-2017]	3-May-2013	Nat'l Stage of KP004.D/WO		PENDING (Published)
KP004.E/US	14070,506 (United States) [Pub'd as US2015/0125539 on 7-May-2015]	2-Nov-2013	CIP of KP004.D/US2	US 9,827,191 on 28-Nov-2017	ISSUED
KP004.E/US2	15/808,746 (United States) [Pub'd as US2018/0064641 on 08-Mar-2018]	9-Nov-2017	CON of KP004.E/US	US10,688,045 on 23-Jun-2020	ISSUED
KP004.E/US3	15/977,911 (United States) [Pub'd as US2018/0280290 on 04-Oct-2018]	11-May-2018	CON of KP004.E/US2	US10,646,436 on 12-May-2020	ISSUED
KP004.E/US4	16/888,371 (United States) [Pub'd as US 2020/0289409 on 29-May-2020]	29-May-2020	DIV of KP004.E/US2	US10,940,108 on 09-Mar-2021	ISSUED
KP004.E/US5	15/977,940 (United States) [Pub'd as US2018/0256497 on 13-Sep-2018]	11-May-2018	CON of KP004.E/US2	US10,646,437 on 12-May-2020	ISSUED
KP004.E/US6	16/221,253 (United States) [Pub'd as US2019/0125758 on 02-May-2019]	14-Dec-2018	CON of KP004.E/US5	US10,864,219 on 15-Dec-2020	ISSUED
KP004.E/US7	16/896,007 (United States) [Pub'd as US 2020/0297624 on 24-Sep-2020]	08-Jun-2020	CON of KP004.E/US5	US10,857,096 on 08-Dec-2020	ISSUED

KP004.E/US8	16/988,459 (United States) [Pub'd as US2020/0368154 on 26-Nov-2020]	07-Aug-2020	CON of KP004.E/US4	US10,945,948 on 16-Mar-2021	ISSUED
KP004.E/US9	16/988,470 (United States) Pub'd as US2020/0368155 on 26-Nov-2020]	07-Aug-2020	CON of KP004.E/US4	US10,993,908 on 04-May-2021	ISSUED
KP004.E/US10	17/170,701 (United States)	08-Feb-2021	CON of KP004.E/US9		PENDING
KP004.E/US11	17/207,442 (United States)	19-Mar-2021	CON of KP004.E/US9		PENDING
KP004.E/US13	17/207,467 (United States)	19-Mar-2021	CON of KP004.E/US9		PENDING
KP004.E/WO	PCT/US2014/063373 (PCT Int'l) [Pub'd as WO2015/066444 on 07-May-2015]	31-Oct-2014	PCT of KP004.E/US		EXPIRED/IN NATL STAGE
KP004.E/AU	2014/342097 (Australia) [Pub'd as AU2014342097 on 12-May-2016]	31-Oct-2014	Natl Stage of KP004.E/WO	AU2014342097 on 21-Dec- 2017	GRANTED
KP004.E/CA	2,928,969 (Canada) [Pub'd as CA2928969 on 07- May-2015]	31-Oct-2014	Natl Stage of KP004.E/WO		PENDING (Published)
KP004.E/CN	201480071942.7 (China) [Pub'd as CN105916509 on 31-Aug-2016]	31-Oct-2014	Natl Stage of KP004.E/WO	CN105916509 on 17-Jun-2020	GRANTED
KP004.E/CN2	202010578302.2 (China) [Pub'd as CN11743878 on 09-Oct-2020]	31-Oct-2014	DIV of KP004.E/CN		PENDING
KP004.E/CN3	202010578480 (China) [Pub'd as CN11743879 on 09-Oct-2020]	31-Oct-2014	DIV of KP004.E/CN		PENDING

KP004.E/EP	14858272.9 (European Patent Office) [Pub'd as EP3062796 on 07-Sep-2016]	31-Oct-2014	Natl Stage of KP004.E/WO		PENDING (Published)
KP004.E/EP2	(European Patent Office)		DIV of KP004.E/EP		In Progress
KP004.E/HK-CN	17100500.4 (Hong Kong) [Pub'd as HK1226949 on 13-Oct-2017]	16-Jan-2017	HK Registration of KP004.E/CN		PENDING (Published)
KP004.E/HK-EP	17100086.6 (Hong Kong) [Pub'd as HK1226333 on 29-Sep-2017]	4-Jan-2017	HK Registration of KP004.E/EP		PENDING (Published)
KP004.E/HK-CN2	42021028763.7 (Hong Kong)		HK Registration of KP004.E/CN2		PENDING
KP004.E/HK-CN3	42021028764.5 (Hong Kong)		HK Registration of KP004.E/CN3		PENDING
KP004.E/IN	201617014248 (India) [Pub'd as IN36/2016 on 31-Aug-2016]	31-Oct-2014	Natl Stage of KP004.E/WO	IN359759 on 26-Feb-2021	Granted
KP004.E/IN2	202018056794 (India)	31-Oct-2014	DIV of KP004.E/IN		PENDING
KP004.E/JP	2016-552253 (Japan) [Pub'd as JP2016535777 on 11-Nov-2016]	31-Oct-2014	Natl Stage of KP004.E/WO	JP6751669 on 19-Aug-2020	GRANTED
KP004.E/JP2	2019-219516 (Japan)	31-Oct-2014	DIV of KP004.E/JP2		PENDING
KP004.E/MX	MX/a/2016/005710 (Mexico) [Pub'd as MX2016005710 on 08-Feb-2017]	31-Oct-2014	Natl Stage of KP004.E/WO		PENDING (Allowed)

OUR REF NO	APPL'N NO & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO & ISSUE DATE	STATUS
PATENT FAMILY: KP005 TITLES): THERAPEUTIC COMPOUNDS AND USES THEREOF Assignee: Kala					
KP004.E/INZ	719182 (New Zealand)	31-Oct-2014	Natl Stage of KP004.E/MO		ABANDONED
KP005.A/USPR	61/765,487 (United States)	15-Feb-2013	Provisional 1		EXPIRED
KP005.A/MO	PCT/US2014/016763 (PCT Int'l) [Pub'd as WO2014/127335 on 21-Aug-2014]	18-Feb-2014	PCT of KP005.A/USPR		EXPIRED/IN NATIONAL STAGE
KP005.A/US	14/768,038 (United States) [Pub'd as US2016/0002254 on 07-Jan-2016]	14-Aug-2015 (371 Date)	Natl Stage of KP005.A/MO	US 9,695,184 on 4-Jul-2017	ISSUED
KP005.B/USPR	61/898,778 (United States)	1-Nov-2013	Provisional 2		EXPIRED
KP005.C/US	14/181,095 (United States) [Pub'd as US2014/0235634 on 21-Aug-2014]	14-Feb-2014	US ORD of KP005.A & .B/USPR	US 9,353,122 on 31-May-2016	ISSUED
KP005.C/US2	15/139,099 (United States) [Pub'd as US2016/0235761 on 18-Aug-2016]	26-Apr-2016	CON of KP005.C/US	US 9,827,248 on 28-Nov-2017	ISSUED
KP005.C/US3	15/139,107 (United States) [Pub'd as US2016/0237093 on 18-Aug-2016]	26-Apr-2016	DIV of KP005.C/US	US 9,877,970 on 30-Jan-2018	ISSUED

KP005.C/US4	15/868,894 (United States) [Pub'd as US2018/0133225 on 17-May-2018]	11-Jan-2018	CON of KP005.C/US3	US10,398,703 on 03-Sep-2019	ISSUED
KP005.C/US5	16/522,550 (United States) [Pub'd as US2020/0054644 on 20-Feb-2020]	25-Jul-2019	CON of KP005.C/US4	US10,966,987 on 06-April-2021	ISSUED
KP005.C/US6	17/180,388 (United States)	19-Feb-2021	CON of KP005.C/US5		PENDING
KP005.C/WO	PCT/US2014/016439 (PCT Int'l) [Pub'd as WO2014/127214 on 21-Aug-2014]	14-Feb-2014	PCT of KP005.A & .B/USPR		EXPIRED/IN NATIONAL STAGE
KP005.C/AU	2014/216,178 (Australia) [Pub'd as AU2014216178 on 03-Sep-2015]	14-Feb-2014	Nat'l Stage of KP005.C/WO	AU2014216178 on 11-Oct-2018	GRANTED
KP005.C/AU2	2018-229493 (Australia)	14-Feb-2014	DIV of KP005.C/AU		To Be Abandoned
KP005.C/CA	2,900,652 (Canada) [Pub'd as CA2900652 on 21- Aug-2014]	14-Feb-2014	Nat'l Stage of KP005.C/WO	CA2900652 on 05-Apr-2021	GRANTED
KP005.C/EP	14751929.2 (European Patent Office) [Pub'd as EP2956138 on 23- Dec-2015]	14-Feb-2014	Nat'l Stage of KP005.C/WO		PENDING (Published)
KP005.C/HK-EP	16105107.1 (Hong Kong) [Pub'd as HK1217092 on 23- Dec-2016]	20-Feb-2014	HK Registration of KP005.C/EP		PENDING (Published)
KP005.C/JP	2015-558148 (Japan) [Pub'd as JP2016513108 on 12-May-2016]	14-Feb-2014	Nat'l Stage of KP005.C/WO	JP6669499 on 18-Mar-2020	GRANTED

PATENT FAMILY: KP006

TITLE(S): THERAPEUTIC COMPOUNDS AND USES THEREOF

Assignee: Kala

OUR REF. NO.	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP006.A/USPR	61/767,087 (United States)	20-Feb-2013	Provisional 1		EXPIRED
KP006.B/USPR	61/898,741 (United States)	1-Nov-2013	Provisional 2		EXPIRED
KP006.C/US	14/184,886 (United States) [Pub'd as US2014/0235657 on 21-Aug-2014]	20-Feb-2014	US ORD of KP006.A & .B/USPR	US 9,353,123 on 31-May-2016	ISSUED
KP006.C/US2	15/139,121 (United States) [Pub'd as US2016/0235753 on 18-Aug-2016]	26-Apr-2016	CON of KP006.C/US	US 9,833,453 on 5-Dec-2017	ISSUED
KP006.C/US3	15/139,135 (United States) [Pub'd as US2016/0237094 on 18-Aug-2016]	26-Apr-2016	DIV of KP006.C/US	US 9,861,634 on 9-Jan-2018	ISSUED
KP006.C/US4	15/842,695 (United States) [Pub'd as US2018/0104246 on 19-Apr-2018]	14-Dec-2017	CON of KP006.C/US3	US10,285,991 on 14-May-2019	ISSUED
KP006.C/US5	16/361,732 (United States) [Pub'd as US2019/0216812 on 18-Jul-2019]	22-Mar-2019	Con of KP006.C/US4	US10,758,539 on 01-Sep-2020	ISSUED
KP006.C/US6	16/915,508 (United States) [Pub'd as US2020/0323854 on 29-Jun-2020]	29-Jun-2020	CON of KP006.C/US5		PENDING
KP006.C/WO	PCT/US2014/017270 (PCT Int'l)	20-Feb-2014	PCT of KP006.A & .B/USPR		EXPIRED/IN NATIONAL STAGE

	[Pub'd as WO2014/130612 on 28-Aug-2014]					
KP006.C/AU	2014/219,024 (Australia) [Pub'd as AU2014/219024 on 05-Apr-2018]	20-Feb-2014	Nat'l Stage of KP006.C/WO	AU2014219024 on 19-Jul-2018	GRANTED	
KP006.C/AU2	2018/202,312 (Australia) [Pub'd as AU2018/202312 on 26-Apr-2018]	20-Feb-2014	DIV of KP006.C/AU	AU2018202312 on 13-Feb-2020	GRANTED	
KP006.C/BR	2015-1120139 (Brazil) [Pub'd as BR112015020139 on 18-Jul-2017]	20-Feb-2014	Nat'l Stage of KP006.C/WO		PENDING (Published)	
KP006.C/CA	2,900,680 (Canada) [Pub'd as CA2900680 on 28-Aug-2014]	20-Feb-2014	Nat'l Stage of KP006.C/WO		PENDING (Allowed)	
KP006.C/CN	2014800212484.8 (China) [Pub'd as CN105189462 on 23-Dec-2015]	20-Feb-2014	Nat'l Stage of KP006.C/WO	CN105189462 on 10-Nov-2017	GRANTED	
KP006.C/CN2	201710946816.7 (China) [Pub'd as CN107915751 on 17-Apr-2018]	20-Feb-2014	DIV of KP006.C/CN		PENDING (Published)	
KP006.C/EP	14754329.2 (European Patent Office) [Pub'd as EP2958895 on 30-Dec-2015]	20-Feb-2014	Nat'l Stage of KP006.C/WO	EP2958895 on 19-Aug-2020	GRANTED	
KP006.C/EP-CH	(Switzerland)		Valid of KP006.C/EP			
KP006.C/EP-DE	(Germany)		Valid of KP006.C/EP			
KP006.C/EP-ES	(Spain)		Valid of KP006.C/EP			

KP006.C/EP-FR	(France)			Valid. of KP006.C/EP		
KP006.C/EP-GB	(Great Britain)			Valid. of KP006.C/EP		
KP006.C/EP-IE	(Ireland)			Valid. of KP006.C/EP		
KP006.C/EP-IT	(Italy)			Valid. of KP006.C/EP		
KP006.C/EP-NE	(Netherlands)			Valid. of KP006.C/EP		
KP006.C/EP2	20191413.2 (European Patent Office) [Pub'd as EP3763710 on 31- Jan-2021]	20-Feb-2014		DIV. of KP006.C/EP		PENDING (Published)
KP006.C/HK-CN2	18113257.1 (Hong Kong) [Pub'd as HK1254296 on 19-Jul-2019]	20-Feb-2014		HK Registration of KP006.C/CN2		PENDING (Published)
KP006.C/HK-EP	16105120.4 (Hong Kong) [Pub'd as HK1217191 on 30- Dec-2016]	20-Feb-2014		HK Registration of KP006.C/MWO		PENDING (Published)
KP006.C/IN	2354/MUMNP/2015 (India) [Pub'd as IN22/2016 on 27- May-2016]	20-Feb-2014		Nat'l Stage of KP006.C/MWO		PENDING (Published)
KP006.C/JP	2015-558936 (Japan) [Pub'd as JP2016510000 on 04-Apr-2016]	20-Feb-2014		Nat'l Stage of KP006.C/MWO		ABANDONED
KP006.C/JP2	2018-229512 (Japan)	20-Feb-2014		DIV. of KP006.C/JP		PENDING (Allowed)

KP006 C/KR	10-2015-7025432 (South Korea) [Pub'd as KR20150119361 on 23-Oct-2015]	20-Feb-2014	Nat'l Stage of KP006 C/WO		PENDING (Allowed)
KP006 C/MX	MX/a/2015/010829 Mexico [Pub'd as MX2015010829 on 03-Dec-2015]	20-Feb-2014	Nat'l Stage of KP006 C/WO	MX368903 on 20-Feb-2020	GRANTED
KP006 C/NZ	711050 (New Zealand)	20-Feb-2014	Nat'l Stage of KP006 C/WO		PENDING
KP006 C/NZDIV	768857 (New Zealand)	20-Feb-2014	DIV of KP006 C/NZ		PENDING
KP006 C/NZ2	750895 (New Zealand)	20-Feb-2014	DIV of KP006 C/NZ		PENDING
KP006 C/NZ2DIV	768858 (New Zealand)	20-Feb-2014	DIV of KP006 C/NZ2		PENDING
KP006 C/NZ3	750897 (New Zealand)	20-Feb-2014	DIV of KP006 C/NZ		PENDING
KP006 C/NZ3DIV	768859 (New Zealand)	20-Feb-2014	DIV of KP006 C/NZ3		PENDING

PATENT FAMILY: KP007

TITLE(S): MEROPENEM DERIVATIVES AND USES THEREOF

Assignee: Kala

OUR REF NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
------------	----------------------	-------------	--------------	-------------------------	--------

KP007.B/AUSPR	61/789,335 (United States)	15-Mar-2013	Provisional		EXPIRED Provisional
KP007.B/MWO	PCT/US2014/028627 (PCT Int'l) [Pub'd as WO2014/144285 on 18-Sep-2014]	14-Mar-2014	PCT of KP007.AUSPR		EXPIRED/ IN NATIONAL STAGE
KP007.B/AU	2014/227737 (Australia) [Pub'd as AU2014227737 on 17-May-2018]	15-Mar-2014	Nat'l Stage of KP007.B/MWO	AUP2014227737 on 30-Aug- 2018	GRANTED
KP007.B/AU2	2018/203,005 (Australia) [Pub'd as AU2018203005 on 17-May-2018]	1-May-2018	DIV of KP007.B/AU		ABANDONED
KP007.B/BR	BR 11 2015 023621 9 (Brazil) [Pub'd as BR112015023621 on 18-Jul-2017]	15-Mar-2014	Nat'l Stage of KP007.B/MWO		ABANDONED
KP007.B/CA	2,906 689 (Canada) [Pub'd as CA2906689 on 18- Sep-2014]	15-Mar-2014	Nat'l Stage of KP007.B/MWO		PENDING (Published)
KP007.B/EP	14762750 9 (European Patent Office) [Pub'd as EP2968274 on 20- Jan-2016]	15-Mar-2014	Nat'l Stage of KP007.B/MWO	EP2968274 on 16-Oct-2019	GRANTED
KP007.B/EP-DE	(Germany)	15-Mar-2014	Validation of KP007.B/EP		
KP007.B/EP-FR	(France)	15-Mar-2014	Validation of KP007.B/EP		
KP007.B/EP-UK	(Great Britain)	15-Mar-2014	Validation of KP007.B/EP		
KP007.B/HK-EP	16107322.6 (Hong Kong) [Pub'd as HK1219233 on 31- Mar-2017]	15-Mar-2014	HK Registration of KP007.B/EP		PENDING (Published)

KP007.B/IN	2654/MUMNP/2015 (India) [Pub'd as IN30/2016 on 22-Jul-2018]	15-Mar-2014	Nat'l Stage of KP007.B/WO		PENDING (Published)
KP007.B/JP	2016-502851 (Japan) [Pub'd as JP2016517435 on 16-Jun-2016]	15-Mar-2014	Nat'l Stage of KP007.B/WO		ABANDONED
KP007.B/JP2	2019-023946 (Japan)	15-Mar-2014	Div. of KP007.B/JP	JP6736918 on 22-Jul-2020	GRANTED
KP007.B/US	14/777,018 (United States) [Pub'd as US2016/0039823 on 11-Feb-2016]	15-Sep-2015 (371 Date)	Nat'l Stage of KP007.B/WO	US 9,725,451 on 8-Aug-2017	ISSUED
KP007.B/US2	15/650,667 (United States) [Pub'd as US2017/0349590 on 07-Dec-2017]	14-Jul-2017	CON of KP007.B/US	US10,392,388 on 27-Aug-2019	ISSUED
KP007.B/US3	16/509,388 (United States) [Pub'd as US2020/0010470 on 09-Jan-2020]	11-Jul-2019	CON of KP007.B/US2		PENDING (Allowed)

PATENT FAMILY: KP008					
TITLE(S): NOVEL COMPOUNDS AND USES THEREOF					
Assignee: Kala					
OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP008.A/USPR	61/829,117 (United States)	30-May-2013	Provisional 1		EXPIRED
KP008.B/USPR	61/898,719 (United States)	1-Nov-2013	Provisional 2		EXPIRED

KP008.C/WO	PCT/US2014/040231 (PCT Int'l) [Pub'd as WO2014/197313 on 11-Dec-2014]	30-May-2014	PCT of KP008.A &.B/USPR		EXPIRED/IN NATIONAL STAGE
KP008.C/AU	2014/275198 (Australia) [Pub'd as AU2014/275198 on 10-Dec-2015]	30-May-2014	Nat'l Stage of KP008.C/WO	AU2014275198 on 30-Jul-2017	GRANTED
KP008.C/CA	2,913,417 (Canada) [Pub'd as CA2913417 on 11- Dec-2014]	30-May-2014	Nat'l Stage of KP008.C/WO		PENDING (Published)
KP008.C/EP	14807232.5 (European Patent Office) [Pub'd as EP3003314 on 13- Apr-2016]	30-May-2014	Nat'l Stage of KP008.C/WO	EP3003314 on 14-May-2019	GRANTED
KP008.C/EP-DE	(Germany)		Validation of KP008.C/EP		
KP008.C/EP-FR	(France)		Validation of KP008.C/EP		
KP008.C/EP-GB	(Great Britain)		Validation of KP008.C/EP		
KP008.C/HK-EP	16111737.7 (Hong Kong) [Pub'd as HK1223307 on 28- Jul-2017]	30-May-2014	HK Registration of KP008.C/EP		ABANDONED
KP008.C/JP	2016-517041 (Japan) [Pub'd as JP2016520617 on 14-Jul-2016]	30-May-2014	Nat'l Stage of KP008.C/WO	JP6557654 on 19-Jul-2019	GRANTED
KP008.C/US	14/894,214 (United States) [Pub'd as US2016/0137646 on 19-May-2016]	25-Nov-2015 (371 Date)	Nat'l Stage of KP008.C/WO	US 9,988,386 on 5-Jun-2018	ISSUED
KP008.C/US2	15/970,740 (United States) [Pub'd as US2018/0251467 on 06-Sep-2018]	3-May-2018	CON of KP008.C/US	US 10,351,570 on 16-Jul-2019	ISSUED

KP008 C/US3	16/014,937 (United States) [Pub'd as US2019/0023710 on 24-Jan-2019]	21-Jun-2018	CON of KP008 C/US2	US10,544,151 on 28-Jan-2020	ISSUED
KP008 C/US4	16/422,606 (United States) [Pub'd as US2020/0157106 on 21-May-2020]	24-May-2019	DIV of KP008 C/US2	US10,954,244 on 23-Mar-2021	ISSUED
KP008 C/US5	17/165,791 (United States)	02-Feb-2021	CON of KP008 C/US4		PENDING

PATENT FAMILY: KP009

TITLE(S): UREA DERIVATIVES AND USES THEREOF

Assignee: *Kala*

GRN REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP009 A/USPR	61/833,853 (United States)	11-Jun-2013	Provisional 1		EXPIRED
KP009 B/USPR	61/898,720 (United States)	1-Nov-2013	Provisional 2		EXPIRED
KP009 C/US	14/301,653 (United States) [Pub'd as US 2015/0072986 on 12-Mar-2015]	11-Jun-2014	US ORD of KP009 A & .B/USPR	US 9,212,145 on 15-Dec-2015	ISSUED
KP009 C/US2	14/939,727 (United States) [Pub'd as US 2016/0060264 on 03-Mar-2016]	12-Nov-2015	DIV of KP009 C/US	US 9,580,421 on 28-Feb-2017	ISSUED
KP009 C/US3	15/411,485 (United States) [Pub'd as US2017/0129876 on 11-May-2017]	20-Jan-2017	DIV of KP009 C/US2	US 9,802,922 on 31-Oct-2017	ISSUED

KP009.C/US4	15/782.696 (United States) [Pub'd as US2018/0037572 on 18-Feb-2018]	12-Oct-2017	CON of KP009.C/US3	US 10,059,692 on 28-Aug-2018	ISSUED
KP009.C/US5	15/782.743 (United States) [Pub'd as US2018/0037573 on 18-Feb-2018]	12-Oct-2017	CON of KP009.C/US3	US 10,059,693 on 28-Aug-2018	ISSUED
KP009.C/US6	16/043,000 (United States) [Pub'd as US2018/0327389 on 15-Nov-2018]	23-Jul-2018	CON of KP009.C/US5	US 10,316,022 on 11-Jun-2019	ISSUED
KP009.C/US7	16/043,007 (United States) [Pub'd as US2018/0327390 on 15-Nov-2018]	26-Jul-2018	CON of KP009.C/US5	US 10,329,280 on 25-Jun-2019	ISSUED
KP009.C/US8	16/400,672 (United States) [Pub'd as US2019/0284172 on 19-Sep-2019]	01-May-2019	CON of KP009.C/US7	US 10,723,719 on 28-Jul-2020	ISSUED
KP009.C/US9	16/900,657 (United States)	12-Jun-2020			PENDING
KP009.C/WO	PCT/US2014/041930 (PCT Int'l) [Pub'd as WO2014/201127 on 18-Dec-2014]	11-Jun-2014	PCT of KP009.A & KP009.B/USPR		EXPIRED/IN NATIONAL STAGE
KP009.C/AU	2014/278231 (Australia) [Pub'd as AU2014/278231 on 24-Dec-2015]	11-Jun-2014	Nat'l Stage of KP009.C/WO	AU2014278231 on 7-Sep-2017	GRANTED
KP009.C/AU2	2017/219063 (Australia) [Pub'd as AU2017/219063 on 14-Sep-2017]	24-Aug-2017	DIV of KP009.C/AU		PENDING (Allowed)
KP009.C/AU3	2020/233692 (Australia)	16-Sep-2020	DIV of KP009.C/AU2		PENDING
KP009.C/CA	2,914,815 (Canada) [Pub'd as CA2914815 on 18-Dec-2014]	11-Jun-2014	Nat'l Stage of KP009.C/WO		PENDING (Published)

KP009.C/EP	14811423.4 (Europe Patent Office) [Pub'd as EP3030239 on 15- Jun-2016]	11-Jun-2014	Natl Stage of KP009.C/WO		PENDING (Allowed)
KP009.C/EP2	(Europe)	11-Jun-2014	DIV of KP009.C/EP		In Progress
KP009.C/HK-EP	16113560.5 (Hong Kong) [Pub'd as HK1225376 on 08- Sep-2017]	28-Nov-2016	HK Registration of KP009.C/EP		PENDING (Published)
KP009.C/JP	2016-519614 (Japan) [Pub'd as JP2016534030 on 04-Nov-2016]	11-Jun-2014	Natl Stage of KP009.C/WO	JP6469661 on 25-Jan-2019	GRANTED
KP009.C/JP2	2019-004872 (Japan)	16-Jan-2019	DIV of KP009.C/JP		ABANDONED
KP009.C/JP3	(Japan)		DIV of KP009.C/JP2		PENDING

PATENT FAMILY: KP011					
TITLE(S) (A)-(D): CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF					
Assignee: Kala					
OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP006.B/USPR	67/898,741 (United States)	1-Nov-2013	Provisional 1		Expired
KP011.A/USPR	62/039,200 (United States)	19-Aug-2014	Provisional 2		Expired

KP011.B/USPR	62/039,192 (United States)	19-Aug-2014	Provisional 3		Expired
KP011.C/USPR	62/039,185 (United States)	19-Aug-2014	Provisional 4		Expired
KP011.D/USPR	62/039,177 (United States)	19-Aug-2014	Provisional 5		Expired
KP011.E/US	14/530,092 (United States) [Pub'd as US2015/0125535 on 7-May-2015]	31-Oct-2014	US ORD of Provisionals 1, 3 & 5	US 9,458,169 on 4-Oct-2016	ISSUED
KP011.E/US2	14/981,105 (United States) [Pub'd as US2016/0115176 on 28-Apr-2016]	28-Dec-2015	DIV of KP011.E/US	US 9,790,232 on 17-Oct-2017	ISSUED
KP011.E/US3	15/712,645 (United States) [Pub'd as US2018/000982 on 11-Jan-2018]	22-Sep-2017	CON of KP011.E/US2	US 10,160,765 on 25-Dec-2018	ISSUED
KP011.E/US4	16/184,760 (United States) [Pub'd as US2019-0077810 on 14-Mar-2019]	08-Nov-2018	CON of KP011.E/US3	US 10,618,906 on 04-Apr-2020	ISSUED
KP011.E/US5	16/184,760 (United States) [Pub'd as US2020-0216459 on 09-Jul-2020]	02-Mar-2020	CON of KP011.E/US4	US10,975,090 on 13-Apr-2021	ISSUED
KP011.E/US6	17/197,702 (United States)	10-Mar-2021	CON of KP011.E/US5		PENDING
KP011.E/WO	PCT/US2014/063444 (PCT Int'l) [Pub'd as WO2015/066482 on 05/07/2015]	31-Oct-2014	PCT of Provisionals 1, 3, & 5		EXPIRED/ IN NATIONAL STAGE
KP011.E/AU	2014/342042 (Australia)	31-Oct-2014	National Stage of KP011.E/WO	AU2014342042 on 30-Nov- 2017	GRANTED

	Pub'd as AU/2014342042 on 12-May-2016]					
KP011.E/CA	2,928,658 (Canada) [Pub'd as CA2928658 on 07-May-2015]	31-Oct-2014	National Stage of KP011.E/WO			ABANDONED
KP011.E/CN	201480065624.X (China) [Pub'd as CN106061261 on 26-Oct-2016]	31-Oct-2014	National Stage of KP011.E/WO	CN106061261 on 24-Apr-2018		GRANTED
KP011.E/CN2	201810252366.6 (China) [Pub'd as CN108530458 on 14-Sep-2018]	31-Oct-2014	DIV of KP011.E/CN			ABANDONED
KP011.E/EP	1485737.2 (European Patent Office) [Pub'd as EP3062618 on 07-Sep-2016]	31-Oct-2014	National Stage of KP011.E/WO	EP3062618 on 05-Feb-2020		GRANTED
KP011.E/EP-DE	(Germany)		EP validation of KP011.E/EP			GRANTED
KP011.E/EP-FR	France		EP validation of KP011.E/EP			GRANTED
KP011.E/EP-GB	(Great Britain)		EP validation of KP011.E/EP			GRANTED
KP011.E/HK-EP	17102021.0 (Hong Kong) [Pub'd as HK1228197 on 03-Nov-2017]	31-Oct-2014	HK Registration of KP011.E/WO	HK1228197 on 05-Feb-2021		GRANTED
KP011.E/IN	201627014017 (India) [Pub'd as IN19/2017 on 12-May-2017]	31-Oct-2014	National Stage of KP011.E/WO			ABANDONED
KP011.E/JP	2016-552255 (Japan) [Pub'd as JP2016535100] on 10-Nov-2016]	31-Oct-2014	National Stage of KP011.E/WO	JP6426194 on 02-Nov-2018		GRANTED

KP011.E/JP2	2018-199914 (Japan)	31-Oct-2014	DIV of KP011.E/JP		ABANDONED
KP011.E/KR	10-2016-7014146 (Korea) [Pub'd as KR20160099084 on 19-Aug-2016]	31-Oct-2014	National Stage of KP011.E/WO		ABANDONED
KP011.E/MX	MX/a/2016/005668 (Mexico) [Pub'd as MX2016005668 on 28-Oct-2016]	31-Oct-2014	National Stage of KP011.E/WO	MX355330 on 16-Apr-2018	GRANTED
KP011.E/NZ	719185 (New Zealand) [Pub'd as NZ719185 on 24- Nov-2017]	31-Oct-2014	National Stage of KP011.E/WO	NZ719185 on 27-Feb-2018	GRANTED

PATENT FAMILY: KP012

TITLE(S): CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

Assignee: *Kala*

OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY REL. P	PATENT NO. & ISSUE DATE	STATUS
KP006.B/USPR	61/898,741 (United States)	1-Nov-2013	Provisional		EXPIRED
KP006.C/US	14/184,886 (United States) [Pub'd as US2014/0235657 on 21-Aug-2014]	20-Feb-2014	Non-Provisional in KP006 family	US9,353,123 on 31-May-2016	ISSUED
KP012.A/WO	PCT/US2014/063630 (PCT Int'l) [Pub'd as WO2015/066584 on 7-May-2015]	3-Nov-2014*	PCT (claims benefit of KP006.B/USPR, & KP006.C/US)		EXPIRED/IN NATIONAL STAGE
KP012.A/AU	2014/341966 (Australia) [Pub'd as AU2014341966 on 12-May-2016]	3-Nov-2014	Nat'l Stage of KP012.A/WO	AU2014341966 on 30-Nov- 2017	GRANTED

KP012.A/CA	2,928,665 (Canada) [Pub'd as CA2928665 on 07- May-2015]	3-Nov-2014	Nat'l Stage of KP012.A/MO		ABANDONED
KP012.A/CA2	3109285 (Canada)		DIV of KP012.A/CA		In Progress
KP012.A/EP	14857110.2 (European Patent Office) [Pub'd as EP3062795 on 07- Sep-2016]	3-Nov-2014	Nat'l Stage of KP012.A/MO		PENDING (Published)
KP012.A/HK-EP	17102022.9 (Hong Kong) [Pub'd as HK1228278 on 03- Nov-2017]	23-Feb-2017	HK Registration of KP012.A/EP		PENDING (Published)
KP012.A/JP	2016-552430 (Japan) [Pub'd as JP2016535779 on 17-Nov-2016]	3-Nov-2014	Nat'l Stage of KP012.A/MO	JP6426195 on 02-Nov-2018	GRANTED
KP012.A/JP2	2018-199872 (Japan)	3-Nov-2014	DIV of KP012.A/JP		ABANDONED
KP012.A/US	15/032,595 (United States) [Pub'd as US2016/0257693 on 8-Sep-2016]	3-Nov-2014 (27-Apr-2016 (371 Date))	Nat'l Stage of KP012.A/MO	US 9,688,688 on 27-Jun-2017	ISSUED
KP012.A/US2	15/604,080 (United States) [Pub'd as US2017/0260193 on 14-Sep-2017]	24-May-2017	CON KP012.A/US	US 9,890,173 on 13-Feb-2018	ISSUED

*NOTE: 11/1/2014 was a Saturday

PATENT FAMILY: KP013

TITLE(S): CRYSTALLINE FORMS OF A THERAPEUTIC COMPOUND AND USES THEREOF

Assignee: Kala

OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
-------------	----------------------	-------------	--------------	-------------------------	--------

KP013.A/USPR	62/084,682 (United States)	26-Nov-2014	Provisional 1		EXPIRED
KP013.B/WO	PCT/US2015/062491 (PCT Int'l) [Pub'd as WO2016/086026 on 2-Jun-2016]	24-Nov-2015	PCT of KP013.A/USPR		EXPIRED/IN NATIONAL STAGE
KP013.B/US	15/529,969 (United States) [Pub'd as US 2017/0313724 on 2-Nov-2017]	25-May-2017	Natl Stage of KP013.B/WO	US 10,253,045 on 09-Apr-2019	ISSUED

PATENT FAMILY: KP014

TITLE(S)): A spec: UREA DERIVATIVE AND USES THEREOF, B spec: 1-AMINO-TRIAZOL(1,5-A)PYRIDINE-SUBSTITUTE UREA DERIVATIVE AND USES THEREOF
Assignee: Kala

OUR REF NO	APPL NO & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO & ISSUE DATE	STATUS
KP014.A/USPR	62/090,045 (United States)	10-Dec-2014	Provisional 1		EXPIRED
KP014.B/WO	PCT/US2015/065076 (PCT Int'l) [Pub'd as WO2016/094710 on 16-Jun-2016]	10-Dec-2015	PCT of KP014.B/USPR		EXPIRED/IN NATIONAL STAGE
KP014.B/AU	2015-360,438 (Australia) [Pub'd as AU2015360438 on 15-Jun-2017]	10-Dec-2015	Natl Stage of KP014.B/WO	AU2015360438 on 24-Jan-2019	GRANTED
KP014.B/CA	2969467 (Canada) [Pub'd as CA2969467 on 16- Jun-2016]	10-Dec-2015	Natl Stage of KP014.B/WO		PENDING (Published)
KP014.B/EP	15814003,8 (European Patent Office) [Pub'd as EP3230272 on 18-Oct-2018]	10-Dec-2015	Natl Stage of KP014.B/WO	EP3230272 on 19-Aug-2020	GRANTED

KP014,B/EP-DE	(Germany)		Validation of EP3230272		
KP014,B/EP-FR	(France)		Validation of EP3230272		
KP014,B/EP-GB	(Great Britain)		Validation of EP3230272		
KP014,B/HK-EP	18104975.1 (Hong Kong) [Pub'd as HK1245274 on 24-Aug-2018]	17-Apr-2018	HK Registration of KP014,B/EP		To Be Abandoned
KP014,B/US	15/534,448 (United States) [Pub'd as US2018/0057489 on 01-Mar-2018]	8-Jun-2017	Natl Stage of KP014,B/WO	US10,174,022 on 08-Jan-2019	ISSUED
KP014,B/US2	16/204,827 (United States) [Pub'd as US2019/0092772 on 28-Mar-2019]	29-Nov-2018	CON of KP014,B/US	US10,875,857 on 29-12-2020	ISSUED
KP014,B/US3	17/112,542 (United States) [Pub'd as US2021/0087192 on 25-Mar-2021]	04-DecDe, 2020	CON of KP014,B/US2		PENDING (Published)

PATENT FAMILY: KP015

TITLE(S)) CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

Assignee: Keva

OUR REF. NO	APPLN NO & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO & ISSUE DATE	STATUS
KP015,A/USPR	62/385,155 (United States)	8-Sep-2016	Provisional 1		EXPIRED

KP015.AUS	15/694,252 (United States) [Pub'd as US2018/0065977 on 08-Mar-2018]	1-Sep-2017	US ORD of KP015.AUSPR	US 10,336,767 on 2-Jul-2019	ISSUED
KP015.AUS2	16/415,848 (United States) [Pub'd as US2019/0270752 on 05-Sep-2019]	17-May-2019	DIV of KP015.AUS	US 10,626,121 on 21-Apr-2020	ISSUED
KP015.AUS3	16/818,033 (United States) [Pub'd as US2020/0216460 on 09-Jul-2020]	13-Mar-2020	CON of KP015.AUS2		PENDING (Allowed)
KP015.AWO	PCT/US2017/049914 (PCT Int'l) [Pub'd as WO2018/048746 on 15-Mar-2018]	1-Sep-2017	PCT Int'l of KP015.AUSPR		EXPIRED/ IN NATIONAL STAGE
KP015.AAU	2017324251 (Australia)	1-Sep-2017	Nat'l phase of KP015.AWO		ABANDONED
KP015.AAU2	202017446 (Australia)	1-Sep-2017	DIV of KP015.AAU		PENDING
KP015.ABR	BR1120190044639 (Brazil)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING
KP015.ACA	3036065 (Canada)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING
KP015.ACN	2017800551059 (China)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING
KP015.AEP	178493623 (Europe)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING
KP015.AEP-HK	62019000441.1 (Hong Kong)	26-Dec-2019	HK registration of KP015.AEP		PENDING
KP015.AJP	2019-513002 (Japan)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING

KP015.A/KR	10-2019-7009753 (Korea)	1-Sep-2017	Nat'l phase of KP015.AW0		PENDING
KP015.A/MX	MX/a/2019/002629 (Mexico) [Pub'd as MX/a/2019/002629 on 19-Nov- 2019]	1-Sep-2017	Nat'l phase of KP015.AW0		PENDING (Published)
KP015.A/NZ	751277 (New Zealand)	1-Sep-2017	Nat'l phase of KP015.AW0		PENDING
KP015.B/USPR	62/385,154 (United States)	8-Sep-2016	Provisional 2		EXPIRED
KP015.B/US	15/694,331 (United States) [Pub'd as US20 18/0065978 on 08-Mar-2018]	1-Sep-2017	US ORD of KP015.B/USPR	US 10,253,036 on 09-Apr-2019	ISSUED
KP015.B/US2	15/694,331 (United States) [Pub'd as US20 19/0194218 on 27-Jun-2019]	26-Feb-2019	DIV of 15/694,331		PENDING (Allowed)
KP015.B/WO	PCT/US2017/049920 (PCT Int'l) [Pub'd as WO2018/048747 on 15-Mar-2018]	1-Sep-2017	PCT Int'l of KP015.B/USPR		EXPIRED/ IN NATIONAL STAGE
KP015.B/AU	2017324713 (Australia)	1-Sep-2017	Nat'l phase of KP015.BW0	AU2017324713 on 26-Nov- 2020	GRANTED
KP015.B/CA	3036336 (Canada)	1-Sep-2017	Nat'l phase of KP015.BW0		PENDING
KP015.B/EP	17849363.1 (Europe)	1-Sep-2017	Nat'l phase of KP015.BW0		PENDING
KP015.C/USPR	62/385,148 (United States)	8-Sep-2016	Provisional 3		EXPIRED

KP015.C/US	15/694,383 (United States) [Pub'd as US2018/0065979 on 08-Mar-2018]	1-Sep-2017	US ORD of KP015.C/USPR	US10,392,399 on 27-Aug-2019	ISSUED
KP015.C/US2	16/513,505 (United States)[Pub'd as US2019/0337963 on 07-Nov- 2019]	16-Jul-2019	DIV of KP015.C/US	US10,766,907 on 08-Sep-2020	ISSUED
KP015.C/WO	PCT/US2017/049931 (PCT Int'l) [Pub'd as WO2018/048750 on 15-Mar-2018]	1-Sep-2017	PCT Int'l of KP015.C/USPR		EXPIRED/ IN NATIONAL STAGE
KP015.C/AU	2017324716 (Australia)	1-Sep-2017	Nat'l phase of KP015.C/WO	AU2017324716 on 26-Nov- 2020	GRANTED
KP015.C/CA	3036340 (Canada)	1-Sep-2017	Nat'l phase of KP015.C/WO		PENDING
KP015.C/EP	17849365.6 (Europe)	1-Sep-2017	Nat'l phase of KP015.C/WO		PENDING

PATENT FAMILY: KP017					
TITLE(S): BIOCHEMICAL BINDING OF RET19 AND VEGFR2 INHIBITORS					
Assignee: Kala					
GRN REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP017.A/USPR	62/575,280 (United States)	20-Oct-2017	Provisional 1		PENDING
KP017.B/WO	PCT/US2018/056751 (PCT) [Pub'd as WO2019079747 on 25-Apr-2019]	19-Oct-2018	PCT of KP017.A/USPR		PENDING (Published)

KP017.B/AU	2018351520 (Australia)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/BR	BR1120200077879 (Brazil)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/CA	3079673 (Canada)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/CN	201880080672.4 (China) [Pub'd as CN11465601A on 28-Jul-2020]	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/EP	EP18801107.6 (Europe) [Pub'd as EP3697775 on 26- Aug-2020]	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/HK-CN	62021024397.3 (Hong Kong)	27-Jan-20121	HK of KP017.B/CN		PENDING
KP017.A/EP-HK	62021026025.8 (Hong Kong)	20-Feb-2021	HK of KP017.A/EP		PENDING
KP017.B/IN	202017017553 (India)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/JP	(Japan) 2020-521977 (Japan)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/KR	10-2020-7014314 (South Korea)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/MX	Mx/a/2020/007183 (Mexico)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING
KP017.B/NZ	763580 (New Zealand)	19-Oct-2018	Nat'l phase of KP017.B/WO		PENDING

KP017.B/US	16/757,305 (United States)	17-Apr-2020	Nat'l phase of KP017.B/WO		PENDING
-------------------	-------------------------------	-------------	---------------------------	--	---------

PATENT FAMILY: KP018

TITLE(S): PARTICLES, COMPOSITIONS, AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS

Assignee: Kala

OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP018.A/USPR	62/395,980 (United States)	16-Sep-2016	Provisional 1		EXPIRED
KP018.B/WO	PCT/US2017/051866 (PCT Int'l) [Pub'd as WO2018/053318 on 22-Mar-2018]	15-Sep-2017	PCT of KP018.A/USPR		EXPIRED/ IN NATIONAL STAGE
KP018.B/US	16/331,472 (United States) [Pub'd as US2019/0216824 on 18-Jul-2019]	07-Mar-2019	Nat'l phase of KP018.B/WO		ABANDONED
KP018.B/CA	3037174 (Canada)	15-Sep-2017	Nat'l phase of KP018.B/WO		To Be Abandoned

PATENT FAMILY: KP019

TITLE(S): PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS

Assignee: Kala

OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS

KP019.A/USPR	62/395,984 (United States)	16-Sep-2016	Provisional 1	EXPIRED
KP019.B/WO	PCT/US2017/051869 (PCT Int'l) [Pubd as WO2018/053321 on 22-Mar-2018]	15-Sep-2017	PCT of KP019.A/USPR	EXPIRED/ IN NATIONAL STAGE
KP019.B/US	16/331,474 (United States) [Pubd as US2019/0216726 on 18-Jul-2019]	07-Mar-2019	Nat'l phase of KP019.B/WO	ABANDONED
KP019.B/CA	3037176 (Canada)	15-Sep-2017	Nat'l phase of KP019.B/WO	To Be Abandoned

PATENT FAMILY: KP022

TITLE(S): PARTICLES, COMPOSITIONS AND METHODS FOR OPTICLAMIC AND/OR OTHER APPLICATIONS

Assignee: Kala

OUR REF. NO	APPL. NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP022.A/WO	PCT/US2017/051873 (PCT Int'l) [Pubd as WO2019/055028 on 21-Mar-2019]	15-Sep-2017	none		ABANDONED

PATENT FAMILY: KP023

TITLE(S): PARTICLES, COMPOSITIONS AND METHODS FOR OPTICLAMIC AND/OR OTHER APPLICATIONS

Assignee: Kala

PATENT FAMILY: KP023					
TITLE(S): PARTICLES, COMPOSITIONS AND METHODS FOR OPTICLAMIC AND/OR OTHER APPLICATIONS					
Assignee: Kala					

OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP023.AUSPR	62/694,805 (United States)	6-Jul-2018	Provisional		EXPIRED

PATENT FAMILY: KP024					
TITLE(S): PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS					
Assignee: Kala					
OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP024.AUSPR	62/694,819 (United States)	6-Jul-2018	Provisional		EXPIRED
KP023/24.BUS	16/502,635 (United States) [Pub'd as US2020-0016084 on 16-Jan-2020]	03-Jul-2019	US ORD Filing of KP23.AUSPR & KP024.USPR		ABANDONED

PATENT FAMILY: KP025					
TITLE(S): Ocular Therapies					
Assignee: Kala					
OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP025.AUSPR	63/027,218 (United States)	19-May-2020	Provisional		PENDING

PATENT FAMILY: KP026					
TITLE(S): Ocular Therapies					
Assignee: Kala					
GUR REF. NO.	APPL. N. NO. & COUNTRY	FILING DATE	FAMILY REL. P.	PATENT NO. & ISSUE DATE	STATUS
KP026.AUSPR	63/027,226 (United States)	19-May-2020	Provisional		PENDING

PATENT FAMILY: KP027					
TITLE(S): Ocular Therapies					
Assignee: Kala					
GUR REF. NO.	APPL. N. NO. & COUNTRY	FILING DATE	FAMILY REL. P.	PATENT NO. & ISSUE DATE	STATUS
KP027.AUSPR	63/136,045 (United States)	11-Jan-2021	Provisional		PENDING

EXHIBIT C

Trademarks

OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KALA FAMILY: DESCRIPTION: Research and development services and technical consultation relating to the development and scientific testing of pharmaceuticals and drug formulation technology MARK:						
KTMM001/US (United States)	85/932,177	14-May-2013	42	4,585,580	12-Aug-14	REGISTERED

OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KALA FAMILY: DESCRIPTION: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a wide range of pharmaceuticals MARK:						
KTMM002/US (United States)	85/932,175	14-May-2013	005	5,401,810	13-Feb-18	REGISTERED

OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KALA FAMILY: DESCRIPTION: Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye MARK:						
KTMM003 TYPE: TRADEMARK (character mark) INVELTY'S						
DESCRIPTION: Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye						
KTMM003/US (United States)	87/492,686	16-Jun-2017	005	5,722,929	09-Apr-19	REGISTERED
KTMM003/CA (Canada)	1873402	15-Dec-2017	005	TMAI,067,229	23-Dec-19	REGISTERED
KTMM003/EUTM (European Union)	017603739	15-Dec-2017	005	017603739	08-Mar-2019	REGISTERED

KTM003/Brexit (EU/UK)	UK00917603739	15-Dec-2017	005	UK00917603739	08-Mar-2019	REGISTERED
KTM003/MX (Mexico)	1986895	15-Dec-2017	5	1860084	15-Dec-17	REGISTERED
KTM003/CN (China)		29-Apr-2020	5			ALLOWED

FAMILY:	TYPE:	TRADEMARK (character mark)	MARK:	STATUS
KTM004/US (United States)		87/492,692	005	ABANDONED
KTM004/CA (Canada)		1873400	N/A	REGISTERED
KTM004/EUTM (European Union)		017604083	005	REGISTERED
KTM004/Brexit (EU/UK)		UK00917604083	005	REGISTERED
KTM004/MX (Mexico)		1986902	005	REGISTERED

FAMILY:	TYPE:	TRADEMARK (character mark)	MARK:	STATUS
KTM005				
DESCRIPTION:	Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye			
ORIG. REF. NO.	APPL. N. NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.
KTM005/US (United States)	87/492,700	16-Jun-2017	005	
				REGISTRATION DATE
				ABANDONED

KTM005/CA (Canada)	1873388	15-Dec-2017	N/A	TMA1,066,019	11-Dec-19	REGISTERED
KTM005/EUTM (European Union)	017604067	15-Dec-2017	005	017604067	2-May-18	REGISTERED
KTM005/Brexit (EU/UK)	UK00917604067	15-Dec-2017	005	UK00917604067	2-May-18	REGISTERED
KTM005/MX (Mexico)	1986896	15-Dec-2017	005	1860085	15-Dec-17	REGISTERED

KALA FAMILY:	KTM006	TYPE:	TRADEMARK (character mark)	MARK:	SUYEIOUS	
DESCRIPTION:	Topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye					
OH/REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	FAMILY REL'P	REGISTRATION DATE	STATUS
KTM006/US (United States)	87/492,704	16-Jun-2017	005			ABANDONED

KALA FAMILY:	KTM007	TYPE:	TRADEMARK (character mark)	MARK:	VISOOVA	
DESCRIPTION:	Topical ophthalmic pharmaceutical preparations; (topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye					
OH/REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM007/US (United States)	87/492,707	16-Jun-2017	005			ABANDONED
KTM007/CA (Canada)	1873393	15-Dec-2017	005	TMA1,066,022	11-Dec-19	REGISTERED
KTM007/EUTM (European Union)	017604059	15-Dec-2017	005	017604059	2-May-2018	REGISTERED
KTM007/Brexit (EU/UK)	UK00917604059	15-Dec-2017	005	UK00917604059	2-May-2018	REGISTERED

KTM007/MX (Mexico)	1986899	15-Dec-2017	005	1860086	15-Dec-2017	REGISTERED
------------------------------	---------	-------------	-----	---------	-------------	------------

QUR REF. NO	APPLN NO.	HEING DATE	INTL CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM008/US (United States)	87/694,659	22-Nov-2017	005	6,301,667	23-Mar-2021	REGISTERED
KTM008/AU (Australia)	1927808	18-May-2018	005	1927808	29-Aug-2018	REGISTERED
KTM008/CA (Canada)	1899974	18-May-2018	N/A	TMAJ,080,021	25-June-2020	REGISTERED
KTM008/CN (China)	31025579	21-May-2018	005	31025579	13-Apr-2019	REGISTERED
KTM008/EUTM (European Union)	017902993	18-May-2018	005	017902993	25-Sept-2018	REGISTERED
KTM008/Brexit (EU/UK)	UK00917902993	18-May-2018	005	UK00917902993	25-Sept-2018	REGISTERED
KTM008/JP (Japan)	2018-66101	21-May-2018	005	6088912	12-Oct-2018	REGISTERED
KTM008/MX (Mexico)	2049861	18-May-2018	005	1932976	08-Oct-2018	REGISTERED
KTM008/KR (Korea)	40 2018 67794	18-May-2018	005	40 1457280	12-Mar-2019	REGISTERED
KTM008/CH (Switzerland)	78781/2018	18-Sep-2018	00 5	727020	06-Feb-2019	REGISTERED
KTM008/UK (United Kingdom)	UK00003311937	18-May-2018	005	UK00003311937	08-17-2018	REGISTERED


TRADEMARK

REEL: 007282 FRAME: 0869

KALA FAMILY:	KTMM009	TYPE:	TRADEMARK (character mark)	MARK:	ZUDREYA
DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; Topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye				
OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE
KTMM009/US (United States)	87/694,665	22-Nov-2017	005		
					STATUS
					ALLOWED

KALA FAMILY:	KTMM010	TYPE:	TRADEMARK (character mark)	MARK:	SOODRYA
DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; Topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye				
OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE
KTMM010/US (United States)	87/694,667	22-Nov-2017	005		
					STATUS
					ALLOWED

KALA FAMILY:	KTMM011	TYPE:	TRADEMARK (design plus words; letters &/or numbers)	MARK:	INVELTYS logo (B&W Eye Design)
DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye				
OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE
					STATUS




KTMO11/US (United States)	88/018,617	28-Jun-2018	005	5,968,321	21-Jan-2020	REGISTERED
-------------------------------------	------------	-------------	-----	-----------	-------------	------------

KALA FAMILY: **KTMO12** TYPE: TRADEMARK (design plus words, letters &/or numbers)

MARK:

INVELTYS
Logo (Green Eye Design)

DESCRIPTION: Pharmaceutical preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye



OUR REF. NO	APP'L N NO. & COUNTRY	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTMO12/US (United States)	88/018,623	28-Jun-2018	005	5,968,322	21-Jan-2020	REGISTERED


KALA FAMILY: **KTMO13** TYPE: TRADEMARK (design)

MARK:


V & B&W Eye
Design

DESCRIPTION: Pharmaceutical preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye

OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM013/US (United States)	88/018,626	28-Jun-2018	005	5,968,323	21-Jan-2020	REGISTERED



OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM014/US (United States)	88/018,632	28-Jun-2018	005	5,968,324	21-Jan-2020	REGISTERED



KALA FAMILY:

KTM014 TYPE: TRADEMARK (design)

MARK:

V & Green Eye Design

DESCRIPTION: Pharmaceutical preparations and substances for the treatment of inflammation and pain, pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders, topical ophthalmic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye

KALA FAMILY:	KTM015 TYPE:	TRADEMARK (character mark)	MARK:	ALMIENCE
--------------	--------------	----------------------------	-------	----------


DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the relief of signs and symptoms of dry eye disease; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; injectable ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye					
OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM015/US (United States)	88/062,537	2-Aug-2018	005			ALLOWED

KALA FAMILY:	KTM016	TYPE:	TRADEMARK (character mark)	MARK:	LUXTRION	
DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the relief of signs and symptoms of dry eye disease; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; injectable ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye					
OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM016/US (United States)	88/062,546	2-Aug-2018	005			ABANDONED

KALA FAMILY:	KTM017	TYPE:	TRADEMARK (character mark)	MARK:	REVALBIS	
DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the relief of signs and symptoms of dry eye disease; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; injectable ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye					
OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTM017/US (United States)	88/062,540	2-Aug-2018	005			ALLOWED

KALA FAMILY:	KTMM018	TYPE:	TRADEMARK (character mark)	MARK:	AMPLIFY	
DESCRIPTION:	Class 5: Pharmaceutical products, namely, drug delivery agents in the form of sterile preserved ophthalmic suspension comprising mucus-penetrating nanoparticles Class 10: Pharmaceutical products, namely, a drug delivery system comprising mucus-penetrating nanoparticles					
OH/REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTMM018/US (United States)	88/066,300	6-Aug-2018	005, 010	5,951,075	31-Dec-2019	REGISTERED

KALA FAMILY:	KTMM019	TYPE:	TRADEMARK (design plus words, letters &/or numbers)	MARK:	EYSUVIS logo (Color Eye Shape)	
DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease					
OH/REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KTMM019/US (United States)	88/708,726	27-Nov-2019	005	6,310,078	30-Mar-2021	REGISTERED



KALA FAMILY:	KTMM020	TYPE:	TRADEMARK (design plus words, letters &/or numbers)	MARK:	EYSUVIS logo (B&W Eye Shape)
DESCRIPTION:	Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease				



OR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATES
KTM020/US (United States)	88/708,748	27-Nov-2019	005	6,310,079	30-Mar-2021	REGISTERED

KALA FAMILY: **KTM021** TYPE: TRADEMARK (character mark)

MARK: **RELELYRA**

DESCRIPTION:

Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances for the treatment of dryness of the eye or dry eye flares; topical ophthalmic pharmaceutical preparations and substances for topical relief of the signs and symptoms of dry eye disease or dry eye flares

OR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATES
KTM021/US (United States)	88/797,027	13-Feb-2020	005			ALLOWED

KALA FAMILY: **KTM022** TYPE: TRADEMARK (character mark)

MARK: **SPEDLYF**

DESCRIPTION:

Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances for the treatment of dryness of the eye or dry eye flares; topical ophthalmic pharmaceutical preparations and substances for topical relief of the signs and symptoms of dry eye disease or dry eye flares

OR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATES
KTM022/US (United States)	88/797,025	13-Feb-2020	005			ALLOWED

KALA FAMILY: **KT1M023** TYPE: TRADEMARK (design plus words, letters &/or numbers)

MARK:

DESCRIPTION: Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease.

EYSUVIS Updated logo (Color Eye Shape)




OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS
KT1M023/US (United States)	90/126,591	08-20-2020	005			ALLOWED

KALA FAMILY: **KT1M024** TYPE: TRADEMARK (design plus words, letters &/or numbers)

MARK:

DESCRIPTION: Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease.

EYSUVIS Updated logo (B&W Eye Shape)



OUR REF. NO	APPL'N NO.	FILING DATE	INT'L CLASS	REGISTRATION NO.	REGISTRATION DATE	STATUS

KTMM024/US (United States)	90/126,587	08-20-2020	005			ALLOWED
-------------------------------	------------	------------	-----	--	--	---------